var title_f28_34_29216="Pemphigoid gestationis ext";
var content_f28_34_29216=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pemphigoid gestationis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Widespread erythematous plaques, bullae, and erosions are present on this patient with extensive disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29216=[""].join("\n");
var outline_f28_34_29216=null;
var title_f28_34_29217="Interlobar fissures on HRCT";
var content_f28_34_29217=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Interlobar fissures on HRCT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The curvilinear interlobar fissures have a thickness of 0.15 mm. The right minor fissure has a boomerang configuration (arrow); inside the boomerang, the middle lobe is visible, surrounded by the right upper lobe. The right major fissure appears as an oblique straight line, delineating the superior segment of the right lower lobe posteriorly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29217=[""].join("\n");
var outline_f28_34_29217=null;
var title_f28_34_29218="Carboxymethylcellulose: Drug information";
var content_f28_34_29218=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carboxymethylcellulose: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/20/39235?source=see_link\">",
"    see \"Carboxymethylcellulose: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Optive&trade; [OTC];",
"     </li>",
"     <li>",
"      Refresh Liquigel&trade; [OTC];",
"     </li>",
"     <li>",
"      Refresh Plus&reg; [OTC];",
"     </li>",
"     <li>",
"      Refresh Tears&reg; [OTC];",
"     </li>",
"     <li>",
"      Tears Again&reg; Night &amp; Day&trade; [OTC];",
"     </li>",
"     <li>",
"      Theratears&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Celluvisc&trade;;",
"     </li>",
"     <li>",
"      Refresh Plus&reg;;",
"     </li>",
"     <li>",
"      Refresh Tears&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F146323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F146319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dry eyes: Ophthalmic: Instill 1-2 drops into eye(s) 3-4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F146320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, ophthalmic, as sodium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tears Again&reg; Night &amp; Day&trade;: 1.5% (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, ophthalmic, as sodium [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refresh Liquigel&trade;: 1% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Optive&trade;: 0.5% (15 mL, 30 mL) [contains glycerin]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refresh Tears&reg;: 0.5% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium [drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Refresh Plus&reg;: 0.5% (0.4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Theratears&reg;: 0.25% (0.6 mL, 15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes gel",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F146313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Artificial tear substitute",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5569803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Optive&trade; may be confused with Optivar&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Tears Again Night &amp; Day Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-0.1% (3.5 g): $8.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Celluvisc Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30): $10.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optive Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-0.9% (5 mL): $4.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optive Sensitive Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-0.9% (1): $0.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Refresh Liquigel Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (15 mL): $8.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Refresh Plus Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (30): $8.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Refresh Tears Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 mL): $8.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Retaine CMC Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (30): $11.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Theratears Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (32): $9.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Ultra Fresh Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (15 mL): $8.34",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F146315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Carmize (GB);",
"     </li>",
"     <li>",
"      Cellufresh (AU, NZ, PH, TH);",
"     </li>",
"     <li>",
"      Cellufresh MD (PH, TH);",
"     </li>",
"     <li>",
"      Celluvisc (AT, AU, CH, DE, DK, FI, FR, GB, GR, IE, IL, IN, IT, NL, NZ, PH, PT, SE, TH, TW, ZA);",
"     </li>",
"     <li>",
"      Celluvisc MD (TH);",
"     </li>",
"     <li>",
"      Clarastill (PH);",
"     </li>",
"     <li>",
"      CMC (PY);",
"     </li>",
"     <li>",
"      Fresh Tears (BR);",
"     </li>",
"     <li>",
"      Fresh Tears Liquigel (BR);",
"     </li>",
"     <li>",
"      Optive (MY);",
"     </li>",
"     <li>",
"      Refresh Celluvisc (CO, EC, MY, PE, TW);",
"     </li>",
"     <li>",
"      Refresh Liquigel (AR, CN, CO, EC, GT, HK, MX, PA, PE, SV, TW, VE);",
"     </li>",
"     <li>",
"      Refresh Plus (AU, KP, MY, NZ, TW);",
"     </li>",
"     <li>",
"      Refresh Plus/Celluvisc (HK);",
"     </li>",
"     <li>",
"      Refresh Tears (AR, CN, CO, CR, EC, GT, HK, IL, KP, MX, MY, PA, PE, SG, SV, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8844 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-218.7.204.208-7855FF150B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29218=[""].join("\n");
var outline_f28_34_29218=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146317\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146318\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146323\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146319\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146320\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146312\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146306\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146313\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5569803\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298975\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218966\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323043\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146315\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8844\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8844|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/20/39235?source=related_link\">",
"      Carboxymethylcellulose: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_34_29219="LAM in tuberous sclerosis";
var content_f28_34_29219=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphangioleiomyomatosis in tuberous sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of lung tissue from a woman with tuberous sclerosis demonstrates cystic changes and postive actin staining (arrows) of smooth muscle fascicles in the cyst walls that are characteristic of lymphangioleiomyomatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Colby, TV, Koss, MN, Travis, WD. Tumors of the Lower Respiratory Tract. Armed Forces Institute of Pathology, Washington, DC.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29219=[""].join("\n");
var outline_f28_34_29219=null;
var title_f28_34_29220="Rickettsialpox";
var content_f28_34_29220=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rickettsialpox",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29220/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29220/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29220/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29220/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29220/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29220/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/34/29220/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rickettsialpox is an uncommon, mite-borne rickettsial disease caused by the agent Rickettsia akari. R. akari was first isolated in 1946 from a patient, mites, and a naturally infected house mouse in Queens, New York [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/1\">",
"     1",
"    </a>",
"    ]. The disease was named rickettsialpox because of its resemblance to chickenpox. The etiologic agent was named Rickettsia akari because the causative agent belonged to the genus Rickettsia and because akari is Greek for \"mite.\" R. akari is a member of the spotted fever group of rickettsiae of which R. rickettsii is the prototype. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=see_link\">",
"     \"Biology of Rickettsia rickettsii infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;R. akari is transmitted to the common house mouse (Mus musculus) by the bloodsucking mite Liponyssoides sanguineus (formerly Allodermanyssus sanguineus). The mouse serves as the reservoir for the disease. L. sanguineus is a small (0.75 to 1.5 mm), colorless arthropod that swells to many times its normal size after a blood meal and becomes bright red in color. L. sanguineus rarely bites humans when mice are plentiful. However, when mouse populations are reduced (eg, by vermin eradication programs), this mite will bite humans and transmit the disease. Although natural infection is thought to occur exclusively by the bite of an infected mite, transmission has occurred in laboratory settings via inhalation of infectious aerosols [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Occurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rickettsialpox has been detected in urban areas in New York, Pittsburgh, Cleveland, Boston, as well as Arizona, Utah, South Africa and the Ukraine. Although over 800 cases of rickettsialpox have been reported since the initial description of the infection in 1946, it is widely assumed that this infection is underrecognized and underreported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rickettsialpox may have a wider geographic occurrence than previously realized. For example, R. akari was isolated from a 36 year-old man from Croatia, an area in which rickettsialpox had not been previously recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/5\">",
"     5",
"    </a>",
"    ]. Others have speculated that R. akari is widespread in southern and Eastern Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/6\">",
"     6",
"    </a>",
"    ]. In another report, sera reactive with R. akari antigens were detected among patients from Mexican states of Yucatan and Jalisco who were initially thought to have dengue fever [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/7\">",
"     7",
"    </a>",
"    ]. Another serosurvey done in southern California suggested that R. akari or an akari-like rickettsiae are present in wild rodents in Orange County, California [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/8\">",
"     8",
"    </a>",
"    ]. A single case of rickettsialpox was diagnosed in a man who worked at a suburban golf course in North Carolina [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incubation period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period for rickettsialpox has not been conclusively established but is thought to range from 10 to 14 days. One patient developed fever nine days after an apparent single exposure to a known focus of infection. In a second, laboratory-acquired case, a primary lesion at the site of inoculation appeared on the seventh day and fever appeared ten days after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rickettsialpox is characterized clinically by a triad of findings which occur in the following order:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Initial skin lesion at the site of the bite of the infected mite",
"     </li>",
"     <li>",
"      Abrupt onset of fever and constitutional symptoms such as chills and myalgia",
"     </li>",
"     <li>",
"      A papulovesicular rash",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most cases have each of the features of this triad. The diagnosis should be suspected when these findings occur in the appropriate epidemiologic setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initial lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial lesion typically begins as a tiny papule that enlarges to 1 to 1.5 cm as it progressively vesiculates and then subsequently forms a dark black crust or eschar. (In rare cases, there is more than one initial lesion.) Eschars develop in the majority (more than 80 to 90 percent) of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. They can appear in virtually any location including the face, extremities, or trunk.",
"   </p>",
"   <p>",
"    The skin surrounding the initial lesion usually becomes erythematous and regional lymphadenopathy is often present. However, the initial lesion and the surrounding skin are rarely tender or pruritic. As a result, patients are often unaware of the initial lesion, which typically heals in two to three weeks without treatment and leaves a small scar at the site of the eschar.",
"   </p>",
"   <p>",
"    Biopsy of the initial lesion characteristically reveals epidermal and dermal necrosis with perivascular and periadnexal inflammation. In a recent study of 13 cases of rickettsialpox, eschars were biopsied in five patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/3\">",
"     3",
"    </a>",
"    ]. Direct fluorescent-antibody testing using anti-R. rickettsii globulin (which cross reacts with R. akari antigens) demonstrated organisms consistent with R. akari and a lymphocytic vasculitis in all five patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Constitutional symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constitutional symptoms typically appear abruptly several days after the initial lesion. Virtually all patients have fever and malaise. Headache is characteristically present and may occasionally be severe enough to suggest infection of the central nervous system, especially if stiff neck is present. The cerebrospinal fluid is typically normal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/11\">",
"     11",
"    </a>",
"    ]. Individual patients may complain of photophobia, conjunctival injection, sore throat, nausea, or vomiting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Papulovesicular rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;A generalized skin rash that is the hallmark of rickettsialpox may occur on the same day or from one to nine days after the onset of constitutional symptoms. The rash of rickettsialpox typically begins as a maculopapular eruption that quickly becomes papulovesicular. These lesions then scab and fall off without scarring. Lesions may be numerous or few in number. They can occur on the face, palms, soles and mucous membranes. In some cases the rash remains maculopapular and never becomes papulovesicular [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukopenia is common during the early febrile stage of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The differential count may reveal a relative lymphocytosis. Hepatitis that resolves coincident with treatment may also occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of rickettsialpox can be established by serologic tests, biopsy of an eschar or the papulovesicular rash, or isolation of the etiologic organism from the blood. The last two methods are only available in a few large medical centers with specialized laboratory facilities and access to specialized fluorescent antibody reagents.",
"   </p>",
"   <p>",
"    The most commonly used diagnostic criterion is a fourfold rise in convalescent titers of complement fixation or indirect fluorescent antibodies using spotted fever group antigens. Such tests are available through most state health departments and the Centers for Disease Control and Prevention.",
"   </p>",
"   <p>",
"    Several other diagnostic options have been devised. Direct immunofluorescence can be used to identify rickettsial organisms in paraffin-embedded biopsy tissue from patients with rickettsialpox [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/3\">",
"     3",
"    </a>",
"    ]. However, such methods cannot distinguish between infection with the numerous other members of the spotted fever group such as R. rickettsii and R. conorii.",
"   </p>",
"   <p>",
"    A monoclonal antibody has been created that reacts with a stable antigen of all spotted fever group rickettsiae [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/13\">",
"     13",
"    </a>",
"    ]. This antibody detects R. akari, as well as other members of the spotted fever group, in paraffin-embedded tissue using immunoperoxidase staining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common disease to mimic rickettsialpox is chickenpox. Rickettsialpox can be distinguished from chickenpox by the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rickettsialpox usually has a coexistent eschar",
"     </li>",
"     <li>",
"      The lesions of chickenpox characteristically appear in crops in contrast to rickettsialpox",
"     </li>",
"     <li>",
"      The mature lesion of chickenpox is a vesicle compared to a papulovesicle with a prominent papular component in rickettsialpox",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rickettsialpox can also be confused with four other rickettsial diseases: Mediterranean spotted fever, Queensland tick typhus, African tick bite fever, and Siberian tick typhus. All of these infections may be associated with localized eschars, but only Queensland tick typhus and African tick bite fever have rashes that are typically or occasionally vesicular. Furthermore, they only occur in restricted geographic areas and a history of travel or residence in an endemic area can usually be elicited.",
"   </p>",
"   <p>",
"    Patients with an enteroviral infection may occasionally have an illness that mimics rickettsialpox, but they generally lack eschar and a true vesiculopapular eruption. Rarely, patients with disseminated gonococcemia have vesiculopustular lesions that superficially resemble the lesions of rickettsialpox; however, these lesions do not form eschars. Rickettsialpox has also been confused with cutaneous anthrax [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/4\">",
"     4",
"    </a>",
"    ]. However, patients with cutaneous anthrax characteristically have local edema out of proportion to the size of the lesions and Gram stain of these lesions should reveal nonsporulating gram-positive rods. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7224?source=see_link\">",
"     \"Clinical manifestations and diagnosis of anthrax\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COURSE AND TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with rickettsialpox have a mild illness and full recovery can be expected even without treatment. In one review, only 12 of 144 patients required hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/11\">",
"     11",
"    </a>",
"    ]. Fatal rickettsialpox has never been described.",
"   </p>",
"   <p>",
"    A case of rickettsialpox in an HIV-infected patient was associated with a prompt recovery after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    therapy, although immunohistochemical staining of biopsied lesions showed relatively large numbers of rickettsiae [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tetracyclines have excellent activity against R. akari. In an older report of 25 patients from a New York City hospital, oxytetracycline, chlortetracycline, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    (at doses of 250 mg orally every six hours) led to resolution of fever and other systemic signs of infection within 48 hours of the institution of therapy in all 25 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/15\">",
"     15",
"    </a>",
"    ]. A similar response was demonstrated in a more recent report of 13 patients: all of those who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    became afebrile within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29220/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of choice for rickettsialpox is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    200 mg orally as a loading dose and then 100 mg orally every 12 hours until the patient has been afebrile and clinically well for 48 to 72 hours. We do not recommend alternative therapy for pregnant women or others who cannot take tetracyclines. Since the illness is a mild, self-limited infection in virtually all patients, it does not seem reasonable to expose the patient to the small risk of an adverse reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1772221\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rickettsialpox is an uncommon, mite-borne rickettsial disease caused by the agent Rickettsia akari. The disease was named rickettsialpox because of its resemblance to chickenpox. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      R. akari is transmitted to the common house mouse by a bloodsucking mite. The mouse serves as the reservoir for the disease. When mouse populations are reduced, this mite will bite humans and transmit the disease. Although natural infection is thought to occur exclusively by the bite of an infected mite, transmission has occurred in laboratory settings via inhalation of infectious aerosols. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incubation period for rickettsialpox has not been conclusively established, but is thought to range from 10 to 14 days. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Incubation period'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rickettsialpox is characterized clinically by a triad of findings including the initial skin lesion at the site of the bite followed by abrupt onset of fever, chills, myalgias and a generalized papulovesicular rash. The initial lesion typically begins as a tiny papule that vesiculates and subsequently forms an eschar. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of rickettsialpox is mainly a clinical one based on characteristic symptoms and signs. A diagnosis of rickettsialpox can be established retrospectively by documenting a fourfold rise in convalescent titers of complement fixation or indirect fluorescent antibodies using spotted fever group antigens. Such tests are available through most state health departments and the Centers for Disease Control and Prevention. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common disease to mimic rickettsialpox is chickenpox. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of choice for rickettsialpox is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (200 mg orally as a loading dose and then 100 mg orally every 12 hours) until the patient has been afebrile and clinically well for 48 to 72 hours. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Course and treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/1\">",
"      Public Health Weekly Reports for NOVEMBER 8, 1946. Public Health Rep 1946; 61:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/2\">",
"      SLEISENGER MH, MURRAY ES, COHEN S. Rickettsialpox case due to laboratory infection. Public Health Rep 1951; 66:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/3\">",
"      Kass EM, Szaniawski WK, Levy H, et al. Rickettsialpox in a New York City hospital, 1980 to 1989. N Engl J Med 1994; 331:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/4\">",
"      Koss T, Carter EL, Grossman ME, et al. Increased detection of rickettsialpox in a New York City hospital following the anthrax outbreak of 2001: use of immunohistochemistry for the rapid confirmation of cases in an era of bioterrorism. Arch Dermatol 2003; 139:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/5\">",
"      Radulovic S, Feng HM, Morovic M, et al. Isolation of Rickettsia akari from a patient in a region where Mediterranean spotted fever is endemic. Clin Infect Dis 1996; 22:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/6\">",
"      Brouqui P, Parola P, Fournier PE, Raoult D. Spotted fever rickettsioses in southern and eastern Europe. FEMS Immunol Med Microbiol 2007; 49:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/7\">",
"      Zavala-Velazquez JE, Yu XJ, Walker DH. Unrecognized spotted fever group rickettsiosis masquerading as dengue fever in Mexico. Am J Trop Med Hyg 1996; 55:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/8\">",
"      Bennett SG, Comer JA, Smith HM, Webb JP. Serologic evidence of a Rickettsia akari-like infection among wild-caught rodents in Orange County and humans in Los Angeles County, California. J Vector Ecol 2007; 32:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/9\">",
"      Krusell A, Comer JA, Sexton DJ. Rickettsialpox in North Carolina: a case report. Emerg Infect Dis 2002; 8:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/10\">",
"      ROSE HM. The clinical manifestations and laboratory diagnosis of rickettsialpox. Ann Intern Med 1949; 31:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/11\">",
"      Greenberg M, Pellitteri O. Rickettsialpox. Bull N Y Acad Med 1947; 23:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/12\">",
"      Madison G, Kim-Schluger L, Braverman S, et al. Hepatitis in association with rickettsialpox. Vector Borne Zoonotic Dis 2008; 8:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/13\">",
"      Walker, DH, Gile, GC, Feng, HM, et al. Diagnosis of spotted fever group rickettsioses by immunohistology with a group-specific antlipopolysaccharide monoclonal antibody (abstract). Lab Invest 1994; 70:128A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/14\">",
"      Sanders S, Di Costanzo D, Leach J, et al. Rickettsialpox in a patient with HIV infection. J Am Acad Dermatol 2003; 48:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29220/abstract/15\">",
"      ROSE HM. The treatment of rickettsialpox with antibiotics. Ann N Y Acad Sci 1952; 55:1019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7909 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29220=[""].join("\n");
var outline_f28_34_29220=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1772221\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Occurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incubation period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initial lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Constitutional symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Papulovesicular rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COURSE AND TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1772221\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=related_link\">",
"      Biology of Rickettsia rickettsii infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7224?source=related_link\">",
"      Clinical manifestations and diagnosis of anthrax",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_34_29221="Mannitol: Patient drug information";
var content_f28_34_29221=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mannitol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     see \"Mannitol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=see_link\">",
"     see \"Mannitol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F191286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aridol&trade;;",
"     </li>",
"     <li>",
"      Osmitrol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F191287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Osmitrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F12602315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is for use only during an asthma test. It is given by breathing in liquid only. You will be closely watched by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat brain swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691397",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help get rid of unwanted substances in the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691296",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during an asthma test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702442",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mannitol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703337",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding in the brain, fluid loss, very bad kidney disease, kidney or heart problems during past use, or water in the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3369819",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding in the brain, recent heart attack, recent stroke, or very high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694896",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705505",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you by a doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029254\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11221 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C7EAEF3114-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29221=[""].join("\n");
var outline_f28_34_29221=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191286\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F191287\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12602315\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029245\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029244\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029249\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029250\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029252\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029247\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029248\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029253\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029254\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=related_link\">",
"      Mannitol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/60/43975?source=related_link\">",
"      Mannitol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_34_29222="Idiopathic pulm fibrosis PA";
var content_f28_34_29222=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76204&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Idiopathic pulmonary fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows diffuse, coarse reticular opacities involving all compartments of both lungs. Dilatation of both central pulmonary arteries indicates pulmonary arterial hypertension and cor pulmonale. Traction bronchiectasis contributes to the cystic and tubular lucencies. The lung volumes are preserved.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29222=[""].join("\n");
var outline_f28_34_29222=null;
var title_f28_34_29223="Approach to the young athlete with chronic knee pain or injury";
var content_f28_34_29223=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the young athlete with chronic knee pain or injury",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29223/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29223/contributors\">",
"     Albert C Hergenroeder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29223/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29223/contributors\">",
"     Joseph Chorley, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29223/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29223/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29223/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/34/29223/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic knee pain in the young athlete may be caused by inadequate rehabilitation of a previous injury or repetitive activity. Chronic knee pain can also be caused by conditions unrelated to sports activity (eg, bone tumors, infection, arthritis, slipped capital femoral epiphysis, Legg-Calv&eacute;-Perthes disease) and these conditions must be considered in the differential diagnosis and evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/1\">",
"     1",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    The approach to chronic knee pain is similar to that for acute pain. The same physical examination techniques are used to evaluate individual structures, although the patient usually is in less pain. Additional techniques and maneuvers are used to detect problems that only occur chronically (eg, the Ober test for iliotibial band syndrome, the Thomas test for quadriceps flexibility).",
"   </p>",
"   <p>",
"    The approach to the young athlete with chronic knee pain will be reviewed here. The causes and treatment of knee pain, and the approach to acute knee pain in the young athlete, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the evaluation of a young athlete with knee pain or injury, it is important to determine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Whether the complaint is acute or chronic. The evaluation of acute complaints is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"       \"Approach to the young athlete with acute knee pain or injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The mechanism of injury. For example, was it triggered by a specific event, or did it arise after repetitive activity? If a specific event was involved, are there videotapes of it, or eyewitnesses who can describe what happened? If repetitive activity was involved, what was the activity? What are the training demands of the activity? Was the patient using the appropriate equipment and sports technique?",
"     </li>",
"     <li>",
"      The location of the pain.",
"     </li>",
"     <li>",
"      Whether there are mechanical symptoms (eg, locking, popping, or catching).",
"     </li>",
"     <li>",
"      Whether the patient has a sense of instability (ie, \"giving way\") or functional limitation.",
"     </li>",
"     <li>",
"      Any history of previous knee injury. If so, how was it evaluated and treated?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific causes of acute and chronic knee pain and injury in young athletes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination of the young athlete with chronic knee pain is similar to that for acute pain and injury, except that an athlete with chronic pain usually has less discomfort than does an athlete with acute pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lower extremities should be exposed distal to the midthigh and the legs compared for symmetry of muscle bulk and overall limb alignment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/3\">",
"     3",
"    </a>",
"    ]. The skin, soft tissues, and joints should be examined for erythema and swelling.",
"   </p>",
"   <p>",
"    The gait and kinetic chain of the lower extremity should be observed. It is important to note variations in alignment, such as genu valgum (knock knees), genu varum (bow legs), pes cavus (high-arched feet), pes planus or pronation (flat feet), and hallux valgus (lateral deviation of the great toe). To the extent that any of these kinetic chain variations interfere with load distribution throughout the lower extremity, they can contribute to overuse injuries of the lower extremities and pelvis. These injuries will recur unless the kinetic chain abnormalities are corrected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6199?source=see_link\">",
"     \"Approach to the child with knock-knees\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27511?source=see_link\">",
"     \"Approach to the child with bow-legs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinician should observe the athlete standing on one foot at a time, and then as he or she slowly flexes the knee of the supporting leg. Weakness in the external rotators of the hip (eg, the piriformis) manifests as excessive internal rotation of the femur, a \"corkscrew\" configuration (ie, the knee of the involved leg moves excessively inward), and instability or unsteadiness. Weakness of the external rotators affects the movement of the patellofemoral joint and the weight-bearing capability of the lower leg; it has implications for the long-term rehabilitation of chronic knee pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination techniques used to diagnose chronic knee injuries of individual structures are the same as those for acute injuries:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      McMurray, modified McMurray, and bounce-home test to evaluate the menisci (",
"      <a class=\"graphic graphic_figure graphicRef57609 \" href=\"UTD.htm?6/33/6676\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Valgus stress test to evaluate the medial collateral ligament (MCL) (",
"      <a class=\"graphic graphic_picture graphicRef77592 \" href=\"UTD.htm?40/37/41552\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Varus stress test to evaluate the lateral collateral ligament (LCL) (",
"      <a class=\"graphic graphic_picture graphicRef69222 \" href=\"UTD.htm?36/46/37600\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anterior drawer, Lachman, and pivot shift test to evaluate the anterior cruciate ligament (ACL) (",
"      <a class=\"graphic graphic_picture graphicRef65914 \" href=\"UTD.htm?16/54/17251\">",
"       picture 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef53350 \" href=\"UTD.htm?41/61/42975\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef60176 \" href=\"UTD.htm?8/23/8563\">",
"       figure 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Posterior drawer and posterior sag test to evaluate the posterior cruciate ligament (PCL) (",
"      <a class=\"graphic graphic_figure graphicRef74928 \" href=\"UTD.htm?39/29/40415\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above maneuvers are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    .) Additional maneuvers that are used in the diagnosis of specific chronic knee complaints are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ANTERIOR KNEE PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of chronic anterior knee pain in sports medicine clinics is patellofemoral dysfunction (PFD) or the patellofemoral pain syndrome. Other causes include Osgood-Schlatter disease, Sinding-Larsen-Johansson (SLJ) syndrome, and patellar tendinitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8726?source=see_link&amp;anchor=H8889684#H8889684\">",
"     \"Causes of chronic knee pain in the young athlete\", section on 'Etiology of chronic knee pain and injury'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Patellofemoral dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PFD complain of pain when ascending or descending stairs, and pain and stiffness when rising from the seated position (the \"theater\" or \"movie-goer\" sign) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/4\">",
"     4",
"    </a>",
"    ]. The onset of PFD symptoms often follows a change in training, such as increased running mileage or pace, adding steps to the workout, squats, longer workouts, or new training techniques.",
"   </p>",
"   <p>",
"    When patients with PFD are asked to point to the spot that is most painful, they may localize the pain to one patellar pole or region, or may point around the entire patella because they cannot specifically localize the pain. These findings are consistent with the current understanding that the source of pain in PFD may be the anterior synovium, the infrapatellar fat pad, the subchondral bone, or the medial or lateral retinacula.",
"   </p>",
"   <p>",
"    The examination of patients with PFD should include palpation of the peripatellar region for pain and crepitus, observation of patellar tracking, and evaluation of dynamic restraints (eg, hamstrings and quadriceps) for tightness, and the medial restraints (eg, vastus medialis obliquus [VMO]) for insufficiency. Weakness of the VMO and tightness of the hamstring or quadriceps contribute to PFD, and can be addressed through rehabilitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bulk and tone of the VMO are assessed with a maximal contraction of the VMO and the knee in full extension. Loss of tone and bulk of the VMO can be seen in any chronic knee condition. However, because the VMO is the principal medial dynamic stabilizer of the patella, loss of function contributes to PFD.",
"   </p>",
"   <p>",
"    Hamstring flexibility is assessed by measuring the popliteal angle. In the supine position, with the hip flexed to 90 degrees and the knee flexed at 90 degrees, the knee is passively extended by the examiner until resistance is met. This test is examiner-dependent, but in the author's experience, a normal angle is approximately 110 to 120 degrees, and girls have a larger popliteal angle than boys. Some clinicians measure the popliteal angle at maximum passive extension rather than the point at which resistance is met, and use full extension as the normal standard. However, the author prefers to measure from the point at which the hamstring starts to tighten with passive knee extension rather than the point of maximum passive extension. Popliteal angles of &lt;100 degrees or asymmetry of the popliteal angles indicate hamstring tightness.",
"   </p>",
"   <p>",
"    Quadriceps muscle flexibility is assessed by passively flexing the knee with the patient prone (ie, the Ely test) (",
"    <a class=\"graphic graphic_figure graphicRef64226 \" href=\"UTD.htm?23/17/23839\">",
"     figure 5",
"    </a>",
"    ); asymmetry is most relevant in this setting. Quadriceps flexibility also is assessed using the Thomas test (",
"    <a class=\"graphic graphic_figure graphicRef67093 \" href=\"UTD.htm?29/7/29823\">",
"     figure 6",
"    </a>",
"    ). In this test, the patient sits on the edge of the examination table and pulls one knee to his or her chest, then lies supine with the second leg falling into passive hip extension. It is important that the knee be held snugly to the chest and the lumbar spine be held in neutral, not lordotic, position while the patient is supine. A positive test, indicating tight hip flexors (eg, iliopsoas and rectus femoris), is demonstrated by the inability of the hip of the second leg to remain extended while the first is fully flexed. The rectus femoris muscle (which crosses both the hip and knee joints) of the second leg is tight if the second hip and knee are unable to passively flex to 90 degrees while lying off the edge of the table.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Osgood-Schlatter disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like PFD, Osgood-Schlatter is a manifestation of overuse of one component of the",
"    <span class=\"nowrap\">",
"     extensor/deceleratory",
"    </span>",
"    mechanism of the knee. It occurs in active adolescents who recently have undergone a rapid growth spurt. The anterior knee pain increases gradually over time, and may be exacerbated by direct trauma, running, jumping, or kneeling. The characteristic physical finding is tenderness over the tibial tuberosity with an otherwise completely normal knee examination. Osgood-Schlatter disease is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=see_link\">",
"     \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Knee extensor tendinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Knee extensor tendinitis (also called jumper's knee), another manifestation of overuse, includes patellar tendinitis, quadriceps tendinitis, and SLJ syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/5\">",
"     5",
"    </a>",
"    ]. Athletes, particularly those involved in running and jumping sports, complain of chronic anterior knee pain that may be worse after going up or down stairs or prolonged sitting.",
"   </p>",
"   <p>",
"    The location of tenderness distinguishes among these disorders: the patellar ligament, superior pole of the patella, and inferior pole of the patella in patellar tendinitis; quadriceps tendinitis; and SLJ syndrome, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/5\">",
"     5",
"    </a>",
"    ]. Unlike patellar and quadriceps tendinitis, in which the tendons primarily are involved, SLJ syndrome affects the attachment of the patellar tendon to the inferior pole of the patella [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/6\">",
"     6",
"    </a>",
"    ]. It probably is caused by repetitive microtrauma leading to traction apophysitis. SLJ syndrome typically affects children between 10 and 13 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     LATERAL KNEE PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of chronic lateral knee pain in the young athlete include chronic lateral meniscal tears, iliotibial band syndrome, and tendinitis of biceps femoris or popliteus muscles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=see_link\">",
"     \"Traumatic causes of acute knee pain and injury in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lateral meniscal tear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a chronic lateral meniscal tear have a subjective history of the knee locking, swelling, and possibly giving way. On physical examination, they have lateral joint line tenderness (",
"    <a class=\"graphic graphic_picture graphicRef70461 \" href=\"UTD.htm?12/54/13152\">",
"     picture 4",
"    </a>",
"    ) and may have a positive McMurray or modified McMurray test (",
"    <a class=\"graphic graphic_figure graphicRef57609 \" href=\"UTD.htm?6/33/6676\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Iliotibial band syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The iliotibial band (ITB) syndrome affects the iliotibial band, which is formed by fascia from hip flexors, extensors, and abductors. ITB syndrome typically occurs in runners and cyclists and is likely caused by a combination of overuse and biomechanical factors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ITB syndrome is characterized by an aching or burning pain at the site where the band courses over the lateral femoral condyle (",
"    <a class=\"graphic graphic_picture graphicRef76147 \" href=\"UTD.htm?24/61/25552\">",
"     picture 5",
"    </a>",
"    ); occasionally, the pain radiates up the thigh toward the hip. Risk factors for developing this syndrome include a varus alignment of the knee, excessive running mileage, worn shoes, or continuous running on uneven terrain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/8\">",
"     8",
"    </a>",
"    ]. The iliotibial tract may also be abnormally shortened.",
"   </p>",
"   <p>",
"    The diagnosis of iliotibial band syndrome should be considered in the active patient with focal tenderness with or without palpable clicking over the lateral femoral condyle, and a knee examination that is otherwise normal. The diagnosis of iliotibial band syndrome is supported by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tenderness along the iliotibial band as it courses over the lateral femoral condyle (approximately 2 to 4 cm proximal to the lateral joint line) (",
"      <a class=\"graphic graphic_picture graphicRef76147 \" href=\"UTD.htm?24/61/25552\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Pain with resisted hip abduction with the knee in full extension.",
"     </li>",
"     <li>",
"      A positive Ober test (",
"      <a class=\"graphic graphic_figure graphicRef63810 \" href=\"UTD.htm?14/41/14992\">",
"       figure 7",
"      </a>",
"      ). The Ober test assesses the tightness of the iliotibial band. It is performed with the patient lying on the unaffected side, with the hip and knee of the unaffected leg both positioned in 90 degrees of flexion. The examiner slightly abducts and extends the affected hip and flexes the knee. The patient is then asked to allow the affected leg to fall to the table passively, without actively adducting the hip (just letting it fall with gravity), while the examiner supports the patient's lower leg. Patients with ITB syndrome are more likely to have limited adduction of the leg with this maneuver (positive Ober test).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tendinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lateral knee pain can be caused by tendinitis of the popliteus or biceps femoris muscles. Tendinitis can usually be diagnosed clinically. Important findings include tenderness of the tendon and increased pain with resisted activity. Patients with popliteus tendinitis have tenderness to palpation in the region of the posterior inferior lateral femoral condyle that increases with resisted internal rotation of the tibia. Patients with biceps femoris tendinitis have tenderness along the biceps tendon that increases with resisted knee flexion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MEDIAL KNEE PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The causes of chronic medial knee pain in the young athlete include osteochondritis dissecans (OCD), pes anserinus tendinitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bursitis, unhealed MCL or medial meniscal injury, plica syndrome, semimembranosus tendinitis, stress fracture of the medial superior tibia, adductor magnus strain, and referred hip pain (eg, Legg-Calve-Perthes disease or slipped capital femoral epiphysis [SCFE]).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Osteochondritis dissecans",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteochondritis dissecans (OCD) is a condition in which a segment of articular cartilage, with its underlying subchondral bone, gradually separates from the surrounding osteocartilaginous tissue (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69442 \" href=\"UTD.htm?25/56/26510\">",
"     image 1",
"    </a>",
"    ). Athletes with OCD of the lateral side of the medial femoral condyle may have activity-related pain with intermittent swelling and locking of the knee. Examination findings include tenderness to palpation of the involved condyle with the knee in flexion. Other findings may be similar to those in patients who have meniscal tears. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=see_link\">",
"     \"Approach to the young athlete with acute knee pain or injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8726?source=see_link&amp;anchor=H8889712#H8889712\">",
"     \"Causes of chronic knee pain in the young athlete\", section on 'Osteochondritis dissecans'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pes anserinus tendinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pes anserinus is the site of insertion of the semitendinosus, gracilis, and sartorius tendons. Pes anserinus tendinitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bursitis is manifest as tenderness over the pes anserinus bursa, in the medial superior region of the tibia (",
"    <a class=\"graphic graphic_picture graphicRef62776 \" href=\"UTD.htm?20/22/20847\">",
"     picture 6",
"    </a>",
"    ). The pain is worsened by resisted contraction of the muscles that insert at the pes anserinus:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Resisted knee flexion (semitendinosus)",
"     </li>",
"     <li>",
"      Resisted forward flexion of the hip with the hip slightly externally rotated, the knee extended, and the patient supine (sartorius)",
"     </li>",
"     <li>",
"      Resisted hip adduction (gracilis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Plica syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plica syndrome is caused by a redundant synovial thickening, usually in the medial superior portion of the medial retinaculum coursing toward the medial quadriceps tendon. Patients may complain of popping or snapping when rising from the seated (knee flexed) position, and the pain may improve during exercise. On examination, the thickened tender plicae may be palpated in the medial superior portion of the knee, and a snapping sensation may be felt during knee extension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of chronic medial knee pain in the young athlete include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Semimembranosus tendinitis, which causes posteromedial knee pain after strenuous activity (eg, prolonged walking, climbing, or running). It is exacerbated by excessive pronation of the foot and internal torsion of the hip or femur [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stress fracture at the medial superior tibia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=see_link&amp;anchor=H14#H14\">",
"       \"Overview of the causes of limp in children\", section on 'Stress fractures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Adductor magnus strain is manifest as pain proximal to the origin of the MCL (approximately 4 cm proximal to the medial joint line) with resisted hip adduction.",
"     </li>",
"     <li>",
"      Chronic MCL injuries are evaluated with the valgus stress test (",
"      <a class=\"graphic graphic_picture graphicRef77592 \" href=\"UTD.htm?40/37/41552\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Chronic medial meniscal injuries are evaluated with the McMurray or modified McMurray test (",
"      <a class=\"graphic graphic_figure graphicRef57609 \" href=\"UTD.htm?6/33/6676\">",
"       figure 1",
"      </a>",
"      ) and joint line palpation (",
"      <a class=\"graphic graphic_picture graphicRef70461 \" href=\"UTD.htm?12/54/13152\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Referred pain from the hip (eg, Legg-Calve-Perthes disease and SCFE) manifests with a limp, and decreases internal rotation and abduction of the hip. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"       \"Slipped capital femoral epiphysis (SCFE)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     POSTERIOR KNEE PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Causes of chronic posterior knee pain include Baker's cyst, gastrocnemius or soleus strain, and deep venous thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Baker's cyst",
"    </span>",
"    &nbsp;&mdash;&nbsp;A Baker's (or popliteal) cyst is a cystic enlargement of synovial tissue into the popliteal space. It may be a true cyst, but more often results from the posterior herniation of a chronic knee effusion. Baker's cysts are associated with degenerative arthropathy and internal derangement (eg, meniscal tears) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/10\">",
"     10",
"    </a>",
"    ]. Large cysts (greater than 4 to 5 cm in length) interfere with full flexion of the knee. Baker's cysts usually can be diagnosed by palpation of the popliteal fossa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrocnemius and soleus muscle strains are manifest by local pain and limited flexibility of the respective muscles. Deep venous thrombosis is typically accompanied by distal swelling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of suspected deep vein thrombosis of the lower extremity\", section on 'Clinical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     RADIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs and magnetic resonance imaging (MRI) are the radiographic modalities most commonly used in the evaluation of chronic knee pain in young athletes when the diagnosis cannot be made on the basis of history and physical examination. Plain radiographs are useful in evaluating for degenerative disease, loose bodies, osteochondritis dissecans, infection, bone tumors, and destructive lesions; they may demonstrate calcification in the tendon attachment in patients with SLJ syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/11\">",
"     11",
"    </a>",
"    ]. Special views may be necessary, depending upon the diagnostic consideration:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lesion of osteochondritis dissecans (on the lateral surface of the medial femoral condyle tunnel) is best demonstrated by the tunnel view.",
"     </li>",
"     <li>",
"      The posterior patella is best evaluated with the sunrise view.",
"     </li>",
"     <li>",
"      The findings of osteoarthritis (eg, narrowing of the joint space and sclerosis of the distal femur and tibial plateau) are best demonstrated on standing anterior-posterior views.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI is better able to demonstrate ligamentous and meniscal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, its use should be limited to patients in whom the diagnosis is in question. For example, if the history and physical examination findings are consistent with an isolated chronic MCL or meniscal injury, the patient should undergo rehabilitative therapy. If the patient responds as expected, MRI is not performed. However, if there is no improvement after an initial period of treatment, MRI may be indicated. This is particularly true if the plan is to undergo diagnostic arthroscopy only if the MRI is abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=see_link\">",
"     \"Treatment of knee injuries in the young athlete\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRI is approximately 90 percent accurate in identifying surgically confirmed ACL and meniscal injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, it is no more accurate than the physical examination of an experienced clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29223/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. For this reason, providers who are unskilled in the knee examination should refer patients with knee complaints to a sports medicine clinician or orthopedic surgeon with training in sports medicine before making arrangements for an MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/29/3539?source=see_link\">",
"       \"Patient information: Meniscal tear (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/43/43697?source=see_link\">",
"       \"Patient information: Osgood-Schlatter disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10071655\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Causes of chronic knee pain in the young athlete included repetitive activity, inadequate rehabilitation and recovery from a prior injury, or conditions unrelated to sports activity (eg, bone infection, bone tumor, arthritis, slipped capital femoral epiphysis, Legg-Calve-Perthes disease). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      History and physical examination by an experienced clinician can determine the cause of the chronic knee pain in up to 90 percent of patients. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of chronic anterior knee pain in sports medicine clinics is patellofemoral dysfunction (PFD) or the patellofemoral pain syndrome. Other causes include Osgood-Schlatter disease, Sinding-Larsen-Johansson (SLJ) syndrome, and patellar tendinitis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Anterior knee pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of chronic lateral knee pain in the young athlete include chronic lateral meniscal tears, iliotibial band syndrome, and tendinitis of biceps femoris or popliteus muscles. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Lateral knee pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The causes of chronic medial knee pain in the young athlete include osteochondritis dissecans (OCD), pes anserinus tendinitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bursitis, unhealed MCL or medial meniscal injury, plica syndrome, semimembranosus tendinitis, stress fracture of the medial superior tibia, adductor magnus strain, and referred hip pain (eg, Legg-Calve-Perthes disease or slipped capital femoral epiphysis [SCFE]). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Medial knee pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of chronic posterior knee pain include Baker's cyst, gastrocnemius or soleus strain, and deep venous thrombosis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Posterior knee pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs and magnetic resonance imaging (MRI) are the radiographic modalities most commonly used in the evaluation of chronic knee pain in young athletes when the diagnosis cannot be made solely on the basis of history and physical examination. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Radiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MRI is approximately 90 percent accurate in identifying surgically confirmed ACL and meniscal injuries. However, it is no more accurate than the physical examination by an experienced clinician. Thus, providers who are unskilled in the knee examination should refer patients with knee complaints to a sports medicine clinician or orthopedic surgeon with training in sports medicine before making arrangements for an MRI. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Radiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/1\">",
"      Muscolo DL, Ayerza MA, Makino A, et al. Tumors about the knee misdiagnosed as athletic injuries. J Bone Joint Surg Am 2003; 85-A:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/2\">",
"      Stanitski CL. Pediatric and adolescent sports injuries. Clin Sports Med 1997; 16:613.",
"     </a>",
"    </li>",
"    <li>",
"     Pasque, CB, McGinnis, DW. Knee. In: Care of the Young Athlete, American Academy of Orthopedic Surgeons and American Academy of Pediatrics, Elk Grove Village, IL 2000. p.377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/4\">",
"      Juhn MS. Patellofemoral pain syndrome: a review and guidelines for treatment. Am Fam Physician 1999; 60:2012.",
"     </a>",
"    </li>",
"    <li>",
"     Tachdjian MO. The knee and leg. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton and Lange, Stamford 1997. p.87.",
"    </li>",
"    <li>",
"     Staheli LT. The lower limb. In: Pediatric Orthopaedics, 3rd, Morrissy RT.  (Ed), Lippincott, Philadelphia 1990. Vol 2, p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/7\">",
"      Khaund R, Flynn SH. Iliotibial band syndrome: a common source of knee pain. Am Fam Physician 2005; 71:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/8\">",
"      Messier SP, Edwards DG, Martin DF, et al. Etiology of iliotibial band friction syndrome in distance runners. Med Sci Sports Exerc 1995; 27:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/9\">",
"      Safran MR, Fu FH. Uncommon causes of knee pain in the athlete. Orthop Clin North Am 1995; 26:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/10\">",
"      Miller TT, Staron RB, Koenigsberg T, et al. MR imaging of Baker cysts: association with internal derangement, effusion, and degenerative arthropathy. Radiology 1996; 201:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/11\">",
"      Medlar RC, Lyne ED. Sinding-Larsen-Johansson disease. Its etiology and natural history. J Bone Joint Surg Am 1978; 60:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/12\">",
"      Lee K, Siegel MJ, Lau DM, et al. Anterior cruciate ligament tears: MR imaging-based diagnosis in a pediatric population. Radiology 1999; 213:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/13\">",
"      Cotten A, Delfaut E, Demondion X, et al. MR imaging of the knee at 0.2 and 1.5 T: correlation with surgery. AJR Am J Roentgenol 2000; 174:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/14\">",
"      Feller JA, Webster KE. Clinical value of magnetic resonance imaging of the knee. ANZ J Surg 2001; 71:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/15\">",
"      Rose NE, Gold SM. A comparison of accuracy between clinical examination and magnetic resonance imaging in the diagnosis of meniscal and anterior cruciate ligament tears. Arthroscopy 1996; 12:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29223/abstract/16\">",
"      Stanitski CL. Correlation of arthroscopic and clinical examinations with magnetic resonance imaging findings of injured knees in children and adolescents. Am J Sports Med 1998; 26:2.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6515 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-EE7AE732F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29223=[""].join("\n");
var outline_f28_34_29223=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10071655\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Maneuvers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ANTERIOR KNEE PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patellofemoral dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Osgood-Schlatter disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Knee extensor tendinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      LATERAL KNEE PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lateral meniscal tear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Iliotibial band syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tendinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MEDIAL KNEE PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Osteochondritis dissecans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pes anserinus tendinitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Plica syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      POSTERIOR KNEE PAIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Baker's cyst",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      RADIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10071655\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6515\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6515|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/56/26510\" title=\"diagnostic image 1\">",
"      Osteochondritis dissecans knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6515|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/33/6676\" title=\"figure 1\">",
"      McMurray test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/61/42975\" title=\"figure 2\">",
"      Anterior drawer test2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/23/8563\" title=\"figure 3\">",
"      Pivot shift test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/29/40415\" title=\"figure 4\">",
"      Posterior drawer test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/17/23839\" title=\"figure 5\">",
"      Ely test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/7/29823\" title=\"figure 6\">",
"      Thomas test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/41/14992\" title=\"figure 7\">",
"      Ober test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6515|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/37/41552\" title=\"picture 1\">",
"      Valgus stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/46/37600\" title=\"picture 2\">",
"      Varus stress test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/54/17251\" title=\"picture 3\">",
"      Lachman test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/54/13152\" title=\"picture 4\">",
"      Joint line palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/61/25552\" title=\"picture 5\">",
"      Palpation lateral femoral condyle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/22/20847\" title=\"picture 6\">",
"      Palpation of anserine bursa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/55/27511?source=related_link\">",
"      Approach to the child with bow-legs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/3/6199?source=related_link\">",
"      Approach to the child with knock-knees",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5273?source=related_link\">",
"      Approach to the young athlete with acute knee pain or injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8726?source=related_link\">",
"      Causes of chronic knee pain in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/12/33994?source=related_link\">",
"      Diagnosis of suspected deep vein thrombosis of the lower extremity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12392?source=related_link\">",
"      Osgood-Schlatter disease (tibial tuberosity avulsion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23706?source=related_link\">",
"      Overview of the causes of limp in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/29/3539?source=related_link\">",
"      Patient information: Meniscal tear (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/43/43697?source=related_link\">",
"      Patient information: Osgood-Schlatter disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/50/28455?source=related_link\">",
"      Traumatic causes of acute knee pain and injury in the young athlete",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/61/4056?source=related_link\">",
"      Treatment of knee injuries in the young athlete",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_34_29224="Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults";
var content_f28_34_29224=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29224/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29224/contributors\">",
"     John Varga, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29224/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29224/contributors\">",
"     John S Axford, DSc, MD, FRCP, FRCPCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29224/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29224/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/34/29224/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term scleroderma is used to describe the presence of thickened, hardened skin (from the Greek &ldquo;scleros&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/1\">",
"     1",
"    </a>",
"    ]. Scleroderma is the hallmark feature of a heterogeneous group of conditions, the classification of which is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44087?source=see_link\">",
"     \"Classification of scleroderma disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Scleroderma may be a clinical feature of limited anatomic extent affecting only the skin and subjacent tissues, or it may be associated with systemic involvement. When the characteristic skin disorder is associated with internal organ involvement, the disease is termed systemic sclerosis (SSc). SSc is subcategorized further into diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc) on the basis of the extent and distribution of skin involvement. lcSSc is commonly associated with the CREST syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Limited cutaneous SSc'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other disorders that may either have typical scleroderma skin changes or those that have scleroderma-like cutaneous involvement are considerations in the differential diagnosis of SSc. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The systemic manifestations of SSc are diverse. Most prominent are abnormalities of the circulation (most notably Raynaud phenomenon) and involvement of multiple organ systems, including the musculoskeletal, renal, pulmonary, cardiac, and gastrointestinal systems, with fibrotic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular complications.",
"   </p>",
"   <p>",
"    The prevalence rates of scleroderma-like conditions range from 4 to 489 cases per million individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Incidence figures for SSc are 0.6 to 122 per million persons per year; the actual prevalence is probably at the high end of the range noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/4\">",
"     4",
"    </a>",
"    ]. There are regional differences in incidence. For example, higher rates are seen in the United States and Australia than in Japan or Europe, and in blacks than whites [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A brief overview of the clinical features of SSc in adults is presented here. The pathogenesis, diagnosis, and treatment of SSc are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=see_link\">",
"     \"Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=see_link\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Localized forms of scleroderma and scleroderma in childhood are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=see_link\">",
"     \"Localized scleroderma in childhood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue, arthralgias, and myalgias are common symptoms in patients with SSc. The frequency of these symptoms is uncertain.",
"   </p>",
"   <p>",
"    One of the few estimates of the type and frequency of general symptoms among those with SSc was reported in a study of 107 patients with established disease (median 10 years, range 1 to 37 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/5\">",
"     5",
"    </a>",
"    ]. The following were the most frequent symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fatigue (76 percent)",
"     </li>",
"     <li>",
"      Stiff joints (74 percent)",
"     </li>",
"     <li>",
"      Loss of strength (68 percent)",
"     </li>",
"     <li>",
"      Pain (67 percent)",
"     </li>",
"     <li>",
"      Sleep difficulties (66 percent)",
"     </li>",
"     <li>",
"      Skin discoloration (47 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less commonly noted symptoms were breathlessness, upset stomach, sore eyes, depression, nausea, and weight loss.",
"   </p>",
"   <p>",
"    The level of fatigue in SSc is comparable to that in rheumatoid arthritis, systemic lupus, or cancer patients in active treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/6\">",
"     6",
"    </a>",
"    ]. The presence of fatigue was associated with poorer physical function and greater pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/5\">",
"     5",
"    </a>",
"    ]. Causes of pain include skin-related discomfort, joint pain, Raynaud phenomenon, and ischemic digital ulcers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SKIN INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin involvement is a nearly universal feature of SSc. It is characterized by variable extent and severity of skin thickening and hardening. The fingers, hands, and face are generally the earliest areas of the body involved. Edematous swelling and erythema may precede skin induration.",
"   </p>",
"   <p>",
"    Other prominent skin manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pruritus in the early stages",
"     </li>",
"     <li>",
"      Edema in the early stages",
"     </li>",
"     <li>",
"      Sclerodactyly",
"     </li>",
"     <li>",
"      Digital ulcers",
"     </li>",
"     <li>",
"      Pitting at the fingertips",
"     </li>",
"     <li>",
"      Telangiectasia",
"     </li>",
"     <li>",
"      Calcinosis cutis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The assessment of skin involvement includes semiquantitative estimation of skin thickness, pliability (hardness), and fixation to underlying structures (tethering). The modified Rodnan skin score is commonly used as an outcome measure in clinical trials. This semi-quantitative score rates the severity of these features from 0 (normal) to 3 (most severe) in 17 distinct areas of the body. Objective approaches to measuring scleroderma skin involvement, such as ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and use of a durometer, are under investigation.",
"   </p>",
"   <p>",
"    The distribution of skin lesions forms the basis for the current classification system of SSc into limited and diffuse forms of the disease (",
"    <a class=\"graphic graphic_table graphicRef80559 \" href=\"UTD.htm?3/41/3741\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44087?source=see_link\">",
"     \"Classification of scleroderma disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographs of the hands may reveal soft tissue calcifications (calcinosis cutis) and resorption of the distal phalangeal tufts (acro-osteolysis). Articular erosions, joint space narrowing, and demineralization are less common radiographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small percentage of patients with SSc have no skin induration (termed SSc sine scleroderma) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/10\">",
"     10",
"    </a>",
"    ]. Although there is no clinically evident skin sclerosis, these patients have characteristic vascular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fibrotic features of systemic disease, including Raynaud phenomenon, gastrointestinal involvement, renal crisis, pulmonary hypertension,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interstitial lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Limited cutaneous SSc",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with limited cutaneous SSc (lcSSc), skin sclerosis is restricted to the hands, the distal forearm, and, to a lesser extent, the face and neck. These patients generally have prominent vascular manifestations, including severe Raynaud phenomenon and cutaneous telangiectasia. Many patients with lcSSc have manifestations of the CREST syndrome (",
"    <strong>",
"     C",
"    </strong>",
"    alcinosis cutis,",
"    <strong>",
"     R",
"    </strong>",
"    aynaud phenomenon,",
"    <strong>",
"     E",
"    </strong>",
"    sophageal dysmotility,",
"    <strong>",
"     S",
"    </strong>",
"    clerodactyly, and",
"    <strong>",
"     T",
"    </strong>",
"    elangiectasia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diffuse cutaneous SSc",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sclerotic skin on the chest, abdomen, or upper arms and shoulders is indicative of diffuse cutaneous SSc (dcSSc). Patients with dcSSc are more likely to have, or to develop, significant internal organ damage due to ischemic injury or fibrosis than those with limited cutaneous SSc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     VASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most characteristic clinical manifestation of vascular dysfunction of SSc is Raynaud phenomenon, defined as sequential color changes in the digits precipitated by cold, stress, or even change in temperatures. Raynaud phenomenon is due to arterial vasoconstriction in the digits. The color changes of pallor (\"white\"), acrocyanosis (\"blue\"), and reperfusion hyperemia (\"red\") are characteristic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Vascular injury and consequent chronic tissue damage underlie other serious complications of SSc, including pulmonary artery hypertension, scleroderma renal crisis, and gastric antral vascular ectasia, and also contribute to the pathogenesis of cardiac and gastrointestinal complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Raynaud phenomenon is classically viewed as reversible vasospasm due to functional changes in the digital arteries of the hands and feet. However, in many patients with SSc, progressive structural changes develop in the small blood vessels, with permanently impaired flow. In such patients, episodes of Raynaud phenomenon may be prolonged and can result in ischemic digital ulceration or infarction.",
"   </p>",
"   <p>",
"    It is important to realize that persons presenting with Raynaud phenomenon may have primary (no definable underlying disease) or secondary Raynaud phenomenon. Whereas Raynaud phenomenon is seen in SSc and other connective tissue diseases, as well as a number of disorders which result in abnormal blood flow (",
"    <a class=\"graphic graphic_table graphicRef77253 \" href=\"UTD.htm?30/50/31532\">",
"     table 2",
"    </a>",
"    ), primary Raynaud phenomenon is common in the general population, occurs in otherwise healthy individuals, and almost always follows a benign course. In patients with lcSSc, Raynaud phenomenon generally precedes other disease manifestations, sometimes by years or even decades. In contrast, in patients with dcSSc, the onset of Raynaud phenomenon generally coincides with, and in some cases may even follow, the appearance of characteristic skin or musculoskeletal manifestations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EXTRACUTANEOUS ORGAN INVOLVEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracutaneous organ involvement is virtually universal in SSc. Along with musculoskeletal involvement, the lungs, kidneys, gastrointestinal tract, and heart are commonly affected (",
"    <a class=\"graphic graphic_table graphicRef67889 \" href=\"UTD.htm?42/17/43292\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gastrointestinal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly 90 percent of patients with either subtype of SSc (dcSSc or lcSSc) have evidence of gastrointestinal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Nearly half of these patients may have no symptoms. These issues are discussed in detail separately but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Esophageal hypomotility and incompetence of the lower esophageal sphincter disease were the earliest described visceral manifestations of SSc. Symptoms principally result from chronic gastroesophageal reflux, with subsequent chronic esophagitis and stricture formation, Barrett's esophagus, and pulmonary microaspiration.",
"   </p>",
"   <p>",
"    Any part of the gastrointestinal tract from mouth to anus may be affected in SSc. Common symptoms of gastrointestinal involvement include dysphagia and choking, heartburn, hoarseness, cough after swallowing, bloating, alternating constipation and diarrhea, pseudo-obstruction and bacterial small bowel overgrowth with malabsorption, and fecal incontinence. Chronic gastroesophageal reflux and recurrent episodes of microaspiration may contribute to the development of interstitial lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/13\">",
"     13",
"    </a>",
"    ]. Vascular ectasia (angiodysplasia) in the antrum of the stomach (\"watermelon stomach\") is frequent and may cause chronic gastrointestinal bleeding and anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pulmonary involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary involvement is seen in more than 70 percent of patients with SSc. The two principal clinical manifestations are interstitial lung disease (also called fibrosing alveolitis or pulmonary fibrosis) and pulmonary vascular disease, leading to pulmonary arterial hypertension (PAH) (",
"    <a class=\"graphic graphic_table graphicRef62662 \" href=\"UTD.htm?12/5/12380\">",
"     table 4",
"    </a>",
"    ). These issues are discussed in detail separately but will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=see_link\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some degree of interstitial lung disease occurs in more than three-quarters of patients with SSc. The most common symptoms are breathlessness on exertion (which may progress to dyspnea at rest) and a nonproductive cough. However, patients may have alveolitis and early pulmonary fibrosis in the absence of respiratory symptoms or physical findings. Chest pain is infrequent and hemoptysis is rare. In advanced disease, auscultation over the lungs reveals \"Velcro\" rales most prominent at the lung bases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pulmonary vascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary vascular disease, primarily pulmonary arterial hypertension, occurs in 10 to 40 percent of patients with SSc and is more common in patients with limited cutaneous disease. Vascular disease may occur with or without concurrent interstitial lung disease. Dyspnea with exertion and diminished exercise tolerance are the most common initial symptoms, but these may be absent until the disease is fairly advanced.",
"   </p>",
"   <p>",
"    Pulmonary arterial hypertension is generally a late complication of SSc. It is typically progressive and, if severe, can lead to cor pulmonale and right-sided heart failure. Thrombosis of the pulmonary vessels is a common late-stage complication and is a frequent cause of death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=see_link\">",
"     \"Cor pulmonale\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of lung cancer is increased in patients with both lcSSc and dcSSc. The incidence rate of malignant lung neoplasms is approximately fivefold higher than that for an age and gender matched subset of the general population. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Cancer risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autopsy studies suggest that 60 to 80 percent of patients with dcSSc have pathologic evidence of kidney damage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Impaired renal reserve may be present in the absence of clinical renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/16\">",
"     16",
"    </a>",
"    ]. Microalbuminuria, a mild elevation in the plasma creatinine concentration,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension is observed in as many as 50 percent of patients, but most do not progress to chronic kidney failure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Scleroderma renal crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe and life-threatening renal involvement develops in approximately 10 to 15 percent of patients. It is far more frequent in patients with dcSSc than lcSSc and almost invariably occurs in the early stages of the disease. This form of renal involvement is characterized by:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute onset of oliguric renal failure",
"     </li>",
"     <li>",
"      Urinalysis that reveals only mild proteinuria with few cells or casts",
"     </li>",
"     <li>",
"      Abrupt onset of moderate to marked or malignant hypertension (although some patients remain normotensive)",
"     </li>",
"     <li>",
"      Microangiopathic hemolysis and thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other features of scleroderma renal crisis may be due to severe hypertension or vasculopathy and include microangiopathic hemolytic anemia and thrombocytopenia, pulmonary edema, headache, blurred vision, and hypertensive encephalopathy, often complicated by generalized seizures.",
"   </p>",
"   <p>",
"    Scleroderma renal crisis is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link\">",
"     \"Scleroderma renal crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic cardiac involvement due to SSc have a poor prognosis, with two- and five-year mortality rates of approximately 60 and 75 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/20\">",
"     20",
"    </a>",
"    ]. Most commonly, cardiac complications are secondary to systemic or pulmonary hypertension, but primary cardiac involvement has been increasingly recognized. The manifestations of primary cardiac involvement in SSc include pericarditis, pericardial effusion, myocardial fibrosis, heart failure, myocarditis associated with myositis, microvascular disease, conduction disturbances, and arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Pericardial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic pericarditis occurs in 7 to 20 percent of patients with SSc, but pathologic evidence of pericardial involvement is observed in 70 to 80 percent at autopsy. Pericardial effusions may be small or large and can develop rapidly.",
"   </p>",
"   <p>",
"    There is an association between pericardial effusion and the development of acute renal failure. Two potential explanations for this association have been suggested. First, pericardial effusion may simply be a marker of active",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe SSc. Second, the presence of a large pericardial effusion could compromise cardiac output, resulting in renal hypoperfusion and triggering a cascade of events culminating in scleroderma renal crisis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=see_link\">",
"     \"Scleroderma renal crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Myocardial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patchy myocardial fibrosis is a pathological hallmark of cardiac involvement in SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/22\">",
"     22",
"    </a>",
"    ]. It is distinguishable from the fibrosis associated with coronary atherosclerotic disease and is independent of the secondary cardiac involvement that may result from pulmonary hypertension. Myocardial fibrosis is thought to result from recurrent vasospasm of small vessels and is often associated with contraction band necrosis, a histological lesion indicative of myocardial ischemia followed by reperfusion. The degree of myocardial fibrosis may be increased in SSc patients with a long history of Raynaud phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myocardial involvement can lead to systolic or more often diastolic ventricular dysfunction. This was illustrated in a Doppler echocardiography study of 570 patients with SSc in which left ventricular systolic and diastolic dysfunction were present in 1 and 18 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/23\">",
"     23",
"    </a>",
"    ]. Higher rates of myocardial dysfunction have been reported with tissue Doppler studies in which the abnormalities were independent of pulmonary artery hypertension or interstitial lung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=see_link\">",
"     \"Tissue Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conduction system disease and arrhythmias are common. They are likely to result from fibrosis of the myocardium and conduction system. Many deaths among SSc patients are sudden, and some may result from a ventricular arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Musculoskeletal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest manifestations of diffuse SSc are swelling of the hands, arthralgia, myalgia, and fatigue.",
"   </p>",
"   <p>",
"    Frank inflammatory arthritis is uncommon in SSc. Joint pain, immobility and contractures develop as the result of fibrosis around tendons and other periarticular structures. Contractures of the fingers from this process are most common, but large joint contractures involving the wrists, elbows, and ankles may also occur. The process is sometimes associated with palpable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    audible deep tendon friction rubs. Tendon friction rubs occur predominantly in patients with dcSSc. The most common sites of involvement are the extensor and flexor tendons of the fingers and wrist, tendons over the elbow (triceps), knee (patellar), and ankle (anterior and posterior tibial, peroneal and Achilles).",
"   </p>",
"   <p>",
"    Some studies suggest that the presence of tendon friction rubs in patients with SSc is a marker for aggressive disease and increased risk of internal organ involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/25\">",
"     25",
"    </a>",
"    ]. Destructive joint disease in a patient with SSc may suggest an overlap syndrome with rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42968?source=see_link\">",
"     \"Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neuromuscular involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuromuscular involvement in SSc is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/778?source=see_link\">",
"     \"Neuromuscular manifestations of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .) The following is a brief summary of the types of neurologic and muscle disorders that have been noted in case reports and series:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cranial, entrapment, peripheral, cutaneous, and autonomic neuropathies",
"     </li>",
"     <li>",
"      Myopathy and inflammatory myositis",
"     </li>",
"     <li>",
"      Less commonly, central nervous system involvement including headache, seizures, stroke, radiculopathy, and myelopathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Genitourinary",
"    </span>",
"    &nbsp;&mdash;&nbsp;SSc in men is very commonly associated with erectile dysfunction, which can be an early and even initial manifestation of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/26\">",
"     26",
"    </a>",
"    ]. This was illustrated in a survey that compared 43 SSc patients to 23 patients with rheumatoid arthritis (RA) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/27\">",
"     27",
"    </a>",
"    ]. Among the SSc patients, 81 percent had self-reported erectile dysfunction versus 48 percent of those with RA. While Raynaud phenomenon was more prevalent in SSc than in RA (86 versus 19 percent), it was not an independent predictor of erectile dysfunction.",
"   </p>",
"   <p>",
"    Women with SSc may also have sexual dysfunction. This is related to decreased vaginal lubrication or constriction of the vaginal introitus. In one study, dyspareunia was present in 56 percent of 60 women with SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of issues related to pregnancy in SSc is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34244?source=see_link\">",
"     \"Systemic sclerosis (scleroderma) and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CANCER RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been several reports examining cancer in association with SSc [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/29-36\">",
"     29-36",
"    </a>",
"    ]; the information that is available indicates a probable increased risk of malignancy in these patients. The most significant association appears to be with lung cancer, which accounts for approximately one-third of the cancers seen in SSc patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/31\">",
"     31",
"    </a>",
"    ]; however, a significantly increased incidence was not noted in a population with a high background rate of lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/34\">",
"     34",
"    </a>",
"    ]. In a study of 632 Australian patients with SSc, 19 developed lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/37\">",
"     37",
"    </a>",
"    ]. Those who smoked were seven times as likely to develop cancer as those who did not. Pulmonary fibrosis and antitopoisomerase antibodies were not risk factors for lung cancer.",
"   </p>",
"   <p>",
"    The issue of malignancy in SSc was assessed in a nationwide population-based, retrospective cohort analysis from Denmark performed between 1977 and 2006; 2046 patients with systemic sclerosis were evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/35\">",
"     35",
"    </a>",
"    ]. Patient records were compared with a cohort from the Danish Cancer Registry. The ratio of cancers in SSc patients to expected cancers (the standardized incidence ratio, SIR) was 1.5 overall. The most frequent cancers were lung (SIR 1.6), hematologic (SIR 2.5), and immune-related (SIR 1.4).",
"   </p>",
"   <p>",
"    A similar, modest increase in the overall risk of malignant disease (SIR 1.55) was also seen in a cohort of 769 patients seen from 1987 to 2002 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/36\">",
"     36",
"    </a>",
"    ]. There was, however, a marked increase in the risk of esophageal carcinoma (SIR 15.9 [95% CI 4.2-27.6]) and oropharyngeal carcinoma (SIR 9.63 [95% CI 2.97-16.3]).",
"   </p>",
"   <p>",
"    The cause of an increased cancer risk in SSc is not well understood. The association with lung and skin cancers suggests that sites of disease activity may be prone to malignant transformation. One study has found a close temporal relationship between the onset of cancer and of scleroderma among patients with autoantibodies to RNA polymerase",
"    <span class=\"nowrap\">",
"     I/III,",
"    </span>",
"    suggesting that tumor antigen expression may initiate a scleroderma-like immune response and drive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/38\">",
"     38",
"    </a>",
"    ]. There are conflicting data regarding whether the presence of antibodies to topoisomerase-I (Scl-70) identifies a population of SSc patients who are more likely to have, or to develop, cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29224/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/4/35905?source=see_link\">",
"       \"Patient information: Raynaud disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/23/28017?source=see_link\">",
"       \"Patient information: Scleroderma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=see_link\">",
"       \"Patient information: Raynaud phenomenon (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SSc is categorized into diffuse cutaneous SSc (dcSSc) and limited cutaneous SSc (lcSSc) subsets on the basis of the extent and distribution of skin involvement. lcSSc is commonly associated with the CREST syndrome. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Skin involvement is a nearly universal feature of SSc and is characterized by variable thickening and hardening of the skin. The fingers, hands, and face are generally the earliest areas of the body involved. Edematous swelling and erythema of the skin generally precedes skin induration. Other skin manifestations can occur. Malaise, fatigue, arthralgias, and myalgias are common. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Skin involvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'General manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most obvious clinical manifestation of vascular dysfunction of SSc is Raynaud phenomenon, which is due to arterial vasoconstriction in the digits. Characteristic sequential color changes in the digits of pallor (\"white\"), acrocyanosis (\"blue\"), and reperfusion hyperemia (\"red\") are precipitated by cold, stress, or even change in temperatures. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Vascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vascular injury and subsequent chronic damage underlie other serious complications of SSc, including pulmonary artery hypertension, scleroderma renal crisis, and gastric antral vascular ectasia, and also contribute to the pathogenesis of cardiac and gastrointestinal complications. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Vascular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Extracutaneous organ involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal involvement is present in most patients and can involve any part of the gastrointestinal tract. Symptoms are present in more than half of patients and most commonly result from chronic gastroesophageal reflux, with subsequent chronic esophagitis and stricture formation, Barrett&rsquo;s esophagus, and abnormal motility. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Gastrointestinal involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pulmonary involvement is seen in more than 70 percent of patients. The principal pulmonary manifestations are interstitial lung disease and pulmonary vascular disease. The latter leads to pulmonary arterial hypertension and is more common in patients with limited cutaneous disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Pulmonary vascular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical renal disease is observed in up to half of patients. Findings may include albuminuria, a mild elevation in the plasma creatinine concentration,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypertension. Pathologic vascular changes are present in the kidneys in 60 to 80 percent of patients with dcSSc. Scleroderma renal crisis, the most serious renal complication, occurs in up to 10 to 15 percent of patients, generally among those with early-stage dcSSc, and is associated with a poor prognosis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Renal disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac disease in SSc may be primary or secondary and is associated with a poor prognosis. Musculoskeletal disease, neuromuscular involvement, and genitourinary involvement may also occur, and the risk of malignancy may be increased. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cardiac disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Musculoskeletal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Neuromuscular involvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22\">",
"       'Genitourinary'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Cancer risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of cancer is increased.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/1\">",
"      Black CM. Scleroderma--clinical aspects. J Intern Med 1993; 234:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/2\">",
"      LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/3\">",
"      Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998; 41:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/4\">",
"      Chifflot H, Fautrel B, Sordet C, et al. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008; 37:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/5\">",
"      Sandusky SB, McGuire L, Smith MT, et al. Fatigue: an overlooked determinant of physical function in scleroderma. Rheumatology (Oxford) 2009; 48:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/6\">",
"      Thombs BD, Bassel M, McGuire L, et al. A systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples. Rheumatology (Oxford) 2008; 47:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/7\">",
"      Scheja A, Akesson A. Comparison of high frequency (20 MHz) ultrasound and palpation for the assessment of skin involvement in systemic sclerosis (scleroderma). Clin Exp Rheumatol 1997; 15:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/8\">",
"      Hesselstrand R, Scheja A, Wildt M, Akesson A. High-frequency ultrasound of skin involvement in systemic sclerosis reflects oedema, extension and severity in early disease. Rheumatology (Oxford) 2008; 47:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/9\">",
"      Avouac J, Guerini H, Wipff J, et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 2006; 65:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/10\">",
"      Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000; 43:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/11\">",
"      Turner R, Lipshutz W, Miller W, et al. Esophageal dysfunction in collagen disease. Am J Med Sci 1973; 265:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/12\">",
"      Akesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Br J Rheumatol 1989; 28:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/13\">",
"      Marie I, Dominique S, Levesque H, et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001; 45:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/14\">",
"      Medsger TA Jr, Masi AT, Rodnan GP, et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 1971; 75:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/15\">",
"      Medsger TA Jr, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 1973; 26:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/16\">",
"      Livi R, Teghini L, Pignone A, et al. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis 2002; 61:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/17\">",
"      Traub YM, Shapiro AP, Rodnan GP, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore) 1983; 62:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/18\">",
"      TUFFANELLI DL, WINKELMANN RK. Systemic scleroderma, A clinical study of 727 cases. Arch Dermatol 1961; 84:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/19\">",
"      Nikpour M, Hissaria P, Byron J, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13:R211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/20\">",
"      Janosik DL, Osborn TG, Moore TL, et al. Heart disease in systemic sclerosis. Semin Arthritis Rheum 1989; 19:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/21\">",
"      Byers RJ, Marshall DA, Freemont AJ. Pericardial involvement in systemic sclerosis. Ann Rheum Dis 1997; 56:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/22\">",
"      Tzelepis GE, Kelekis NL, Plastiras SC, et al. Pattern and distribution of myocardial fibrosis in systemic sclerosis: a delayed enhanced magnetic resonance imaging study. Arthritis Rheum 2007; 56:3827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/23\">",
"      de Groote P, Gressin V, Hachulla E, et al. Evaluation of cardiac abnormalities by Doppler echocardiography in a large nationwide multicentric cohort of patients with systemic sclerosis. Ann Rheum Dis 2008; 67:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/24\">",
"      Meune C, Avouac J, Wahbi K, et al. Cardiac involvement in systemic sclerosis assessed by tissue-doppler echocardiography during routine care: A controlled study of 100 consecutive patients. Arthritis Rheum 2008; 58:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/25\">",
"      Steen VD, Medsger TA Jr. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum 1997; 40:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/26\">",
"      Walker UA, Tyndall A, Ruszat R. Erectile dysfunction in systemic sclerosis. Ann Rheum Dis 2009; 68:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/27\">",
"      Hong P, Pope JE, Ouimet JM, et al. Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis. J Rheumatol 2004; 31:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/28\">",
"      Bhadauria S, Moser DK, Clements PJ, et al. Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am J Obstet Gynecol 1995; 172:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/29\">",
"      Rosenthal AK, McLaughlin JK, Gridley G, Nyr&eacute;n O. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/30\">",
"      Kyndt X, Hebbar M, Queyrel V, et al. [Systemic scleroderma and cancer. Search for predictive factors of cancer in 123 patients with scleroderma]. Rev Med Interne 1997; 18:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/31\">",
"      Bielefeld P, Meyer P, Caillot D, et al. [Systemic scleroderma and cancers: 21 cases and review of the literature]. Rev Med Interne 1996; 17:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/32\">",
"      Hill CL, Nguyen AM, Roder D, Roberts-Thomson P. Risk of cancer in patients with scleroderma: a population based cohort study. Ann Rheum Dis 2003; 62:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/33\">",
"      Derk CT, Rasheed M, Spiegel JR, Jimenez SA. Increased incidence of carcinoma of the tongue in patients with systemic sclerosis. J Rheumatol 2005; 32:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/34\">",
"      Chatterjee S, Dombi GW, Severson RK, Mayes MD. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005; 52:2415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/35\">",
"      Olesen AB, Svaerke C, Farkas DK, S&oslash;rensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010; 163:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/36\">",
"      Derk CT, Rasheed M, Artlett CM, Jimenez SA. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/37\">",
"      Pontifex EK, Hill CL, Roberts-Thomson P. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007; 66:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/38\">",
"      Shah AA, Rosen A, Hummers L, et al. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010; 62:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/39\">",
"      Rothfield N, Kurtzman S, Vazques-Abad D, et al. Association of anti-topoisomerase I with cancer. Arthritis Rheum 1992; 35:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29224/abstract/40\">",
"      Derk CT, Sakkas LI, Rasheed M, et al. Autoantibodies in patients with systemic sclerosis and cancer: a case-control study. J Rheumatol 2003; 30:1994.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7551 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29224=[""].join("\n");
var outline_f28_34_29224=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SKIN INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Limited cutaneous SSc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diffuse cutaneous SSc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      VASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EXTRACUTANEOUS ORGAN INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gastrointestinal involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pulmonary involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pulmonary vascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Myocardial disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Musculoskeletal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neuromuscular involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Genitourinary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CANCER RISK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7551\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7551|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/41/3741\" title=\"table 1\">",
"      Systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/50/31532\" title=\"table 2\">",
"      Factors associated with Raynauds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/17/43292\" title=\"table 3\">",
"      Features of systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/5/12380\" title=\"table 4\">",
"      Signs of lung disease in scleroderma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/3/44087?source=related_link\">",
"      Classification of scleroderma disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26329?source=related_link\">",
"      Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/17/36119?source=related_link\">",
"      Cor pulmonale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43095?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40985?source=related_link\">",
"      Localized scleroderma in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/778?source=related_link\">",
"      Neuromuscular manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/4/35905?source=related_link\">",
"      Patient information: Raynaud disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/49/30481?source=related_link\">",
"      Patient information: Raynaud phenomenon (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/23/28017?source=related_link\">",
"      Patient information: Scleroderma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34244?source=related_link\">",
"      Systemic sclerosis (scleroderma) and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7897?source=related_link\">",
"      Tissue Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42968?source=related_link\">",
"      Undifferentiated systemic rheumatic (connective tissue) diseases and overlap syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_34_29225="Local treatment of burns: Topical antimicrobial agents and dressings";
var content_f28_34_29225=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Local treatment of burns: Topical antimicrobial agents and dressings",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29225/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29225/contributors\">",
"     Mayer Tenenhaus, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29225/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29225/contributors\">",
"     Marc G Jeschke, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29225/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29225/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/34/29225/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H21593871\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Local treatment of burns includes cleansing and debridement, topical antimicrobial agents, and dressings. A variety of antimicrobial agents and dressings have been evaluated for the primary therapy of minor and superficial partial-thickness burns, and as the initial treatment of deeper burns prior to excision and skin grafting. Superficial partial-thickness burns devoid of an epithelium and deeper burns are treated with a topical antimicrobial agent and dressing. However, there is no consensus on which topical antimicrobial agent or dressing is best suited for burn wound coverage to prevent or control infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Minor burns (eg, sunburns) and superficial partial-thickness burns with an intact epidermis do not require a topical antimicrobial agent or dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most frequently used topical antimicrobial agents and dressings for burns in adults and children will be reviewed here. The classification, emergent care of burns, and specialized management of burns to the hand are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=see_link\">",
"     \"Treatment of minor thermal burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=see_link\">",
"     \"Primary operative management of hand burns\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593914\">",
"    <span class=\"h1\">",
"     LOCAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healing of a burn wound is a dynamic process, and local management may vary with the evolving clinical picture. Acute burn wounds should, if possible, be evaluated and treated by an experienced burn care provider. Conservative, nonoperative therapies include cleansing, debridement, topical antimicrobial drugs, and dressing changes.",
"   </p>",
"   <p>",
"    Burn wound dressings serve three purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      They absorb drainage",
"     </li>",
"     <li>",
"      They provide protection and a measure of isolation from the environment",
"     </li>",
"     <li>",
"      They decrease wound pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593921\">",
"    <span class=\"h2\">",
"     Cleansing and debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cleansing and debridement remove loose, devitalized, and necrotic tissue (eg, blister, foreign material, and debris). Burn wounds are initially gently and carefully cleansed with either skin disinfectants or mild soap and water. Debridement is typically performed using gentle mechanical techniques (eg, brushing, scraping, curetting, and cutting) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/5\">",
"     5",
"    </a>",
"    ]. In our practice, we generally prefer to begin with well-moistened soft gauze or cotton laparotomy pads. When more aggressive debridements are required, we will often use well-moistened",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    surgical scrub brushes.",
"   </p>",
"   <p>",
"    A variety of proteolytic enzymes has also been used for debridement of burn wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/6\">",
"     6",
"    </a>",
"    ]. These products may be beneficial when removing superficial eschar and pseudoeschar. However, they should",
"    <strong>",
"     not",
"    </strong>",
"    be used in infected sites or in areas in which there is a risk of ocular contamination. Some patients develop an allergic reaction to the enzymes.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Collagenase is probably the most commonly employed enzymatic debriding agent currently commercially available in the US. It is slow acting, requiring several days to a week to adequately debride or heal intermediate depth partial-thickness wounds. In a prospective study of 78 children sustaining partial-thickness burns and treated with collagenase A, 49 (63 percent) had total removal of the eschar [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/7\">",
"       7",
"      </a>",
"      ]. There was no statistical difference in time to achieving a clean burn wound when compared to children with similar burns treated with excision and skin grafting and failing collagenase A treatment (n = 29) and historic controls treated with early excision and skin grafting (n = 41).",
"     </li>",
"     <li>",
"      Bromelain, a papain derivative, is a newer, more aggressive enzymatic agent. A preliminary study of 22 patients with acute deep burns showed that bromelain provided a rapid, effective, selective, and safe method of burn debridement [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/8\">",
"       8",
"      </a>",
"      ]. Patients did experience minor to moderate pain with this agent. An NIH clinical trial is not yet open to accrual at the time of this publication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After judicious debridement, the wound site is typically treated with topical antimicrobial agents and nonadherent dressings. (See",
"    <a class=\"local\" href=\"#H21593928\">",
"     'Topical antimicrobial agents'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H21593997\">",
"     'Dressings'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1054478388\">",
"    <span class=\"h3\">",
"     Burn blisters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of burn blisters depends in part, upon whether or not the blister has ruptured. Ruptured blisters should be debrided, while the best treatment for an intact burn blister remains a matter of debate and experience as there is no accepted standard [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/9\">",
"     9",
"    </a>",
"    ]. In the absence of well-designed studies, experts may come to differing conclusions. As an example, some feel that there is an increased risk of infection in intact blisters, while others feel that the blister acts as a barrier to infection. We prefer not to disrupt very small blisters if they are maintained in a clean, protected, and moist environment. In our practice, we unroof larger blisters and treat accordingly.",
"   </p>",
"   <p>",
"    Potential reasons to rupture intact blisters include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large and expanding blisters may exert pressure on the underlying wound surface",
"     </li>",
"     <li>",
"      Intact blisters can hinder the assessment of burn depth",
"     </li>",
"     <li>",
"      Components of blister fluid are harmful to wound healing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Potential reasons for preserving a burn blister include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blisters may provide a natural barrier against infection",
"     </li>",
"     <li>",
"      Blister fluid may promote wound healing",
"     </li>",
"     <li>",
"      Wound desiccation may occur in the absence of topical antimicrobial agents and adequate dressings",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593928\">",
"    <span class=\"h2\">",
"     Topical antimicrobial agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn wound surfaces are prone to rapid bacterial colonization with the potential for invasive infection. The use of topical antimicrobial agents and aggressive wound care has reduced the incidence of invasive wound infections for superficial partial-thickness burns devoid of epithelium, superficial full-thickness burns, and deeper burns [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/10\">",
"     10",
"    </a>",
"    ]. Topical antimicrobial agents and cytoprotective dressings are the best choices for wound coverage, although there is no consensus on which topical agent or dressing is best suited for burn wound management [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1\">",
"     1",
"    </a>",
"    ]. Randomized trials comparing different topical antimicrobials have been performed, but most had methodologic shortcomings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minor burns (eg, sunburns) and superficial partial-thickness burns with an intact epidermis do not require a topical antimicrobial agent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. For these burns, coverage with bismuth-impregnated petroleum based gauze (eg, Xeroform) is satisfactory. (See",
"    <a class=\"local\" href=\"#H21593990\">",
"     'Bismuth-impregnated petroleum gauze'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Commonly used topical agents for partial-thickness burns include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    , conventional antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , povidone-iodine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/2/36899?source=see_link\">",
"     mafenide",
"    </a>",
"    , and bismuth-impregnated petroleum gauze [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1,11\">",
"     1,11",
"    </a>",
"    ]. These agents have variable degrees of local or systemic adverse effects, and may impede wound healing (",
"    <a class=\"graphic graphic_table graphicRef81801 \" href=\"UTD.htm?14/8/14477\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The selection and application of topical antimicrobials are to a great degree reflected in the art of the science. The preferred agent is dependent upon regional and individual preference and experience, a particular wound quality or state, and the patient&rsquo;s allergy history. Over the past several decades,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/2/36899?source=see_link\">",
"     mafenide",
"    </a>",
"    acetate dressings likely predominated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593935\">",
"    <span class=\"h3\">",
"     Silver sulfadiazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     Silver sulfadiazine",
"    </a>",
"    cream (SSD 1 percent) is the most commonly used burn wound dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. This thick white cream is applied once or twice daily, and can be soothing. SSD and related agents should",
"    <strong>",
"     not",
"    </strong>",
"    be used in women who are pregnant or breastfeeding, or in infants younger than two months old [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SSD cream has antibacterial activity as demonstrated by decreased colonization of burn wounds. However, there are no well-designed trials to confirm improved wound healing or a reduced rate of bacterial wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. In addition, there are potential adverse effects. As an example, SSD will form a pseudoeschar that is loose at the edges, which can promote bacterial proliferation. The pseudoeschar requires removal or debridement to improve the ability to monitor the wound state and facilitate reepithelialization. For wounds covering more than 50 to 60 percent of total body surface area, SSD does not consistently prevent or suppress bacterial growth, particularly of Gram-negative bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SSD impedes reepithelialization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, SSD should be stopped when there is evidence of reepithelialization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593943\">",
"    <span class=\"h4\">",
"     Cerium plus SSD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerium nitrate, one of the lanthanide rare earth elements, can be added to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    (SSD) for cutaneous burns that are not undergoing immediate excision and closure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/14-17\">",
"     14-17",
"    </a>",
"    ]. There have been conflicting reports in adult and pediatric burn patients regarding the clinical value of cerium, as measured by mortality, length of hospital stay, and bacterial colonization of the wounds. In a randomized trial of 60 patients with moderate to severe burns who were treated with SSD-cerium or SSD alone, SSD-cerium had the following significant benefits: reepithelialization occurred eight days earlier, planned skin grafting was performed 11 days earlier, and the duration of hospitalization was seven days shorter (24 versus 31 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/15\">",
"     15",
"    </a>",
"    ]. Other randomized trials, which did not address these clinical outcomes, found that SSD-cerium was not more effective than SSD alone in reducing burn wound colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593951\">",
"    <span class=\"h3\">",
"     Combination antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polysporin is the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    zinc and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"     polymyxin B",
"    </a>",
"    sulfate. When used in combination, this antibiotic ointment can be used to treat partial-thickness burns, especially those that involve the face and perineum [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/11\">",
"     11",
"    </a>",
"    ]. Bacitracin and polymyxin are nontoxic to the wound, but their efficacy in the treatment of infected wounds has not been clearly established.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     Neomycin",
"    </a>",
"    is frequently mixed with bacitracin and polymyxin to reduce the risk of adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/11\">",
"     11",
"    </a>",
"    ]. Ease of application and of removal for wound cleansing are advantages of these preparations compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593959\">",
"    <span class=\"h3\">",
"     Chlorhexidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     Chlorhexidine gluconate",
"    </a>",
"    , a long-lasting antimicrobial skin cleanser, is often used with a gauze dressing for burn wound coverage in superficial partial-thickness burns.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     Chlorhexidine",
"    </a>",
"    dressings do not interfere with wound reepithelialization in contrast to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593967\">",
"    <span class=\"h3\">",
"     Mafenide acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/2/36899?source=see_link\">",
"     Mafenide",
"    </a>",
"    acetate, a potent carbonic anhydrase inhibitor, is used for treating patients with dense bacterial proliferation of the burn wound [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In a prospective study of 669 burn patients treated with 5 percent mafenide solution as either the initial topical antimicrobial agent (276 patients) or for chronic treatment, effective antibacterial activity was achieved, only 1 percent experienced pain severe enough to discontinue therapy, and there was a very low incidence of rash and pruritus and no cases of metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593975\">",
"    <span class=\"h3\">",
"     Povidone-iodine ointment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Povidone-iodine ointment, including a liposomal preparation, effectively combines antisepsis therapy with a desired moist wound environment. Despite a broad spectrum of antimicrobial activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], use of povidone-iodine containing products in burn care is controversial because of cytotoxicity and delay in wound reepithelialization [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/22\">",
"     22",
"    </a>",
"    ]. Another drawback to povidone-iodine ointment compared to other topical agents is that it must be applied four times a day for maximal antimicrobial effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593990\">",
"    <span class=\"h3\">",
"     Bismuth-impregnated petroleum gauze",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bismuth-impregnated petroleum based gauze (eg, Xeroform) is comparable to the topical antimicrobial agents previously described to prevent or control burn wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Bismuth-impregnated gauze is applied as a single layer over the burn and then covered with a bulky dressing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/13\">",
"     13",
"    </a>",
"    ]. This is an excellent option for very small superficial partial-thickness burns where clinical judgement indicates that an antimicrobial agent is not necessary.",
"   </p>",
"   <p>",
"    Bismuth-impregnated petroleum based gauze is a preferred dressing for use in clean partial-thickness wounds, donor sites as well as a nonadherent dressing over skin grafts. It is rather inexpensive and affords mild antimicrobial properties [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4324758\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other agents, such as Dakins solution (0.025 percent sodium hypochlorite) and combinations of antimicrobials with topical antifungal agents, have demonstrated some efficacy for the local treatment of burns [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, there is no official standard for testing efficacy and cytotoxicity of topical antimicrobial agents [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21593997\">",
"    <span class=\"h2\">",
"     Dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The burn wound dressing provides a variety of benefits. It protects the wound from further trauma or infection, provides comfort and pain relief, and promotes healing. After the initial assessment and cleansing, superficial partial-thickness burn wounds can be dressed with a variety of dressing choices. There is no consensus on which topical agent or dressing is best suited for superficial partial-thickness burn wounds and a review of 26 randomized trials (most with methodologic shortcomings) did not identify an optimal dressing type [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Burn wounds are generally cleansed and dressed daily. More frequent dressing changes are performed if there is a large amount of exudate, weeping, or infection. Frequent dressings that are unnecessary can impair burn wound reepithelialization.",
"   </p>",
"   <p>",
"    Three types of dressings can be used for burn management:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Compresses",
"     </li>",
"     <li>",
"      Biosynthetics",
"     </li>",
"     <li>",
"      Biologics",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594004\">",
"    <span class=\"h3\">",
"     Compresses",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several types of compress dressings: fine mesh gauze (preferably with topical antimicrobials), hydrocolloid dressings, and silver-containing dressings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594011\">",
"    <span class=\"h4\">",
"     Fine mesh gauze",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine mesh gauze in combination with antimicrobial agents is the most widely used compress dressing, providing a moister and less adherent dressing than fine mesh gauze alone. (See",
"    <a class=\"local\" href=\"#H21593928\">",
"     'Topical antimicrobial agents'",
"    </a>",
"    above.) This is one of the most common burn wound dressings.",
"   </p>",
"   <p>",
"    Use of fine mesh gauze alone is more likely to lead to scab formation, and the gauze and scab will lift spontaneously as reepithelialization occurs. However, pain can be significant when the gauze is manually removed during dressing changes. As a result, gauze alone is primarily used when there are no other options (eg, topical antimicrobials are not available).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594019\">",
"    <span class=\"h4\">",
"     Hydrocolloid dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrocolloid dressings contain gelatin, pectin, and sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/34/29218?source=see_link\">",
"     carboxymethylcellulose",
"    </a>",
"    in an adhesive polymer matrix, which forms a gel whenever the inner layer contacts the wound exudate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, some hydrocolloid wafers contain silver. These dressings are best used as a treatment of superficial partial-thickness burns that comprise a limited body surface area and are in the later phase of reepithelialization.",
"   </p>",
"   <p>",
"    Five clinical trials that included 314 patients compared hydrocolloid dressings with other conventional burn wound dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1\">",
"     1",
"    </a>",
"    ]. The hydrocolloid dressings were changed every five days as per protocol whereas conventional comparator dressing changes varied from twice daily to every three to five days based upon an indication of leakage or infection. Hydrocolloid dressings significantly reduced mean healing time (10.2 versus 15.6 days) and pain score (1.1 versus 2.3 out of 10 as most severe), and had a better level of patient satisfaction when compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    gauze dressings. There was no difference in healing rates, background pain, pain associated with dressing changes, or ease of removal when comparing hydrocolloid dressings with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    impregnated paraffin gauze with or without silver",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594027\">",
"    <span class=\"h4\">",
"     Silver containing dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Silver containing dressings slowly release silver into the wound. Activated silver has broad spectrum antimicrobial activity and may also have an antiinflammatory benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/30\">",
"     30",
"    </a>",
"    ]. There are several silver containing preparations including nanocrystalline silver (eg, Acticoat, Aquacel Ag),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    , each of which has its own management requirements. Nanocrystalline silver dressings are composed of a urethane film embedded with elemental silver that provides sustained release of silver into the wound. These dressings can be changed once per week, depending upon the amount of exudate [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/31\">",
"     31",
"    </a>",
"    ]. Some nanocrystalline silver dressings (eg, Acticoat) require frequent moistening with water to maintain activation. Older silver formulations that contain silver nitrate and silver",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    require more frequent dressing changes.",
"   </p>",
"   <p>",
"    A variety of clinical trials has been performed with the different silver preparations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 13 trials of patients with burns compared dressings containing silver formulations (including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"       silver sulfadiazine",
"      </a>",
"      ) with non-silver dressings [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/32\">",
"       32",
"      </a>",
"      ]. There were conflicting results regarding reduction of infections with silver containing dressings and insufficient evidence to establish whether these dressings promote wound healing or prevent wound infection. Some trials in this review suggested that there may be a detrimental effect from silver containing dressings.",
"     </li>",
"     <li>",
"      A meta-analysis of five clinical trials compared nanocrystalline silver dressings to older silver formulation dressings (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"       silver sulfadiazine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"       silver nitrate",
"      </a>",
"      ) for evaluation of infection rate, pain, length of hospital stay, and costs [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/33\">",
"       33",
"      </a>",
"      ]. The nanocrystalline silver group had a significantly lower rate of infections (9.5 versus 27.8 percent), decreased pain, no clear effect on hospital length of stay, and a higher cost per patient.",
"     </li>",
"     <li>",
"      A prospective trial comparing Acticoat with Allevyn, an occlusive moist-healing environment material, found that skin graft donor sites dressed with Allevyn reepithelialized at a significantly faster rate, but that there was no difference in the incidence of positive wound cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/34\">",
"       34",
"      </a>",
"      ]. A similar prospective trial found contrary information regarding reepithelialization of skin graft donor site wounds [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/35\">",
"       35",
"      </a>",
"      ]. In this study, Acticoat provided significantly faster reepithelialization and better comfort with Acticoat as a dressing for skin graft donor site wounds than Allevyn. Both studies are in agreement that there is no difference in bacterial colonization of the donor site.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594043\">",
"    <span class=\"h3\">",
"     Biosynthetic dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biosynthetic dressings (semibiologic skin substitutes) are temporary dressings that have been developed in an attempt to reduce the number of dressing changes and facilitate healing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The type of skin substitute depends upon the appearance of the wound, desired outcome, cost efficacy, availability, the clinician's experience, and cultural preferences as some contain a porcine product. The semipermeable nature of these dressings allows wound exudate to be absorbed by the external bulky dressing. A review of 20 clinical trials found that bioengineered skin substitutes were at least as effective as topical agents and wound dressings, or allografts for the management of partial-thickness burns [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/38\">",
"     38",
"    </a>",
"    ]. Biosynthetic dressings are contraindicated for use in infected wounds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594051\">",
"    <span class=\"h4\">",
"     Biobrane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biobrane",
"    <sup>",
"     &reg;",
"    </sup>",
"    is a bilaminate membrane that contains a thin semipermeable silicon membrane bonded to a layer of nylon fabric mesh and coated with a monomolecular layer of type 1 porcine collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/39\">",
"     39",
"    </a>",
"    ]. The porcine collagen provides a hydrophilic coating for fibrin growth that promotes wound adherence. The membrane is porous and permits drainage of exudate and absorption of topical antimicrobial agents. Biobrane is versatile and has additional properties of flexibility, elasticity, and transparency for wound observation. Biobrane has no inherent antimicrobial activity.",
"   </p>",
"   <p>",
"    Biobrane is used to treat excised full-thickness burns in adults, large surface area burns, and burns involving the hands, feet, and joints in adults and children [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. Clinical experience with Biobrane is limited. The largest retrospective review evaluated 84 children with superficial partial-thickness burns or scalds, extending between 5 and 25 percent total body surface area; all were treated with Biobrane [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/45\">",
"     45",
"    </a>",
"    ]. Biobrane adhered to the wound in 71 (84 percent) and there were no infections. Five patients had local nonadherence with no evidence of infection in the aspirate. Cosmetic healing was favorable as 21 of 49 patients (43 percent) had no scars or limited hypopigmented or normal pigmented scars. Most scars that did occur were hypopigmented with softness between minimal and middle resistance.",
"   </p>",
"   <p>",
"    Biobrane is applied by gently stretching the fabric over the burn surface to avoid wrinkles and is secured to non-burned skin with paper strips [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/45\">",
"     45",
"    </a>",
"    ]. Dry gauze is used to cover the Biobrane and the dressings are secured with an elastic bandage. The external dressings are changed every 24 hours, and any fluid accumulating under the Biobrane is aspirated. Biobrane can be left in place for up to 14 days, then removed in a warm bath or trimmed. Healed wounds are treated with topical agents or creams. If there is evidence of a wound infection, the Biobrane is removed and the burn treated with topical antimicrobials. (See",
"    <a class=\"local\" href=\"#H21593928\">",
"     'Topical antimicrobial agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594058\">",
"    <span class=\"h4\">",
"     Biobrane-like",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are biosynthetic dressings that either incorporate Biobrane or are of a similar nature including Transcyte&reg; (neonatal fibroblast incorporated into Biobrane), Suprathel&reg; (resorbable caprolactone based materials), Omiderm&reg; (hydrophilized polyurethane membrane), and AWBAT.",
"   </p>",
"   <p>",
"    Ten clinical trials compared the effectiveness of Biobrane or Transcyte to twice a day application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    or other comparators [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/1\">",
"     1",
"    </a>",
"    ]. Overall, biosynthetic dressings resulted in a shorter time to healing, improved pain relief during dressing changes, lower requirement for pain medication, and a shorter length of hospital stay. Pooled data were not provided. A prospective trial of 30 patients with partial-thickness burns compared Suprathel to Omiderm [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/46\">",
"     46",
"    </a>",
"    ]. Suprathel provided significantly better attachment and adherence to wounds, improved pain score, and ease of application, but there was no difference in healing time and time to reepithelialization. Further comparative studies are required.",
"   </p>",
"   <p>",
"    AWBAT, a derivative of Biobrane, is a porous silicone-nylon membrane coated with porcine type 1 collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/47\">",
"     47",
"    </a>",
"    ]. A prospective single arm trial of 18 superficial burn wounds in 15 patients found good adherence, no fluid accumulation, no infections, low pain scores, transparency, conformability, and pliability [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/48\">",
"     48",
"    </a>",
"    ]. A multicenter, randomized clinical trial comparing AWBAT to Xeroform&trade; (petroleum gauze) or Glucan II&trade; (beta-glucan collagen dressing) for the treatment of donor sites in burn surgery is recruiting patients as of July 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/49\">",
"     49",
"    </a>",
"    ]. Beta-glucan collagen, which combines a carbohydrate with collagen, is an effective dressing that adheres to the burn within 24 hours, allows reepithelialization with minimal pain, and provides an excellent cosmetic result [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102063607\">",
"    <span class=\"h4\">",
"     Polyhexanide containing bio-cellulose",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective trial of 60 patients with partial-thickness burns found that patients treated with a polyhexanide containing bio-cellulose dressing (BWD+PHMB) had significantly better and faster burn pain reduction compared with patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"     silver sulfadiazine",
"    </a>",
"    cream (day 0 &lt;1 versus &gt;5 by the Visual Analog Scale) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/51\">",
"     51",
"    </a>",
"    ]. The reduction in pain with BWD+PHMB continued for 14 days of observation. BWD+PHMB was also more cost-effective. The material is available for clinical use in the European Union. A variety of interactive dressings have been used for the treatment of partial thickness wounds with none of them showing superiority. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594072\">",
"    <span class=\"h3\">",
"     Biologic dressings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several biologic dressings are used as temporary coverage for burn wounds. Biologic dressings or bismuth-impregnated petroleum gauze are especially useful in children, as they are applied only once, decreasing the pain that typically accompanies wound dressing changes. Biologic dressings can be used on clean burn wounds, and they protect the wound from desiccation while promoting reepithelialization. These dressings will separate from the wound when it has reepithelialized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594080\">",
"    <span class=\"h4\">",
"     Allogeneic skin grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient physiologic coverage can be achieved by allogeneic skin grafts (eg, from a non-genetically identical donor, also called homograft) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/52\">",
"     52",
"    </a>",
"    ]. Allografts are distributed as either fresh or cryopreserved after glycerol preservation from cadavers. The application of an allograft over superficial partial-thickness wounds can minimize pain and facilitate reepithelialization. Allogeneic skin is generally used only in burn centers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594087\">",
"    <span class=\"h4\">",
"     Human amnion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human amniotic membrane has been successfully employed as a biologic dressing for partial-thickness wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. A retrospective review of 31 studies found that amniotic membrane promotes reepithelialization of the burn wound, has antimicrobial properties, and reduces pain, fluid loss, and scar formation. Concerns regarding pathogenic transmission have limited its use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594094\">",
"    <span class=\"h4\">",
"     Skin xenografts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin xenografts (heterografts) are obtained from an unrelated species and used as temporary skin coverage, especially for large burn wounds. Only porcine grafts are currently used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Xenografts are more readily available, but not as effective as allografts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11194486\">",
"    <span class=\"h1\">",
"     LOCAL TREATMENT OF PRURITUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe pruritus occurs in as many as 87 percent of adult and 100 percent of pediatric burn patients during the healing process [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Pruritus tends to present early during wound healing and continues well after reepithelialization and scar maturation, but rarely persists beyond 18 months. An overview of the treatment of pruritus in general is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=see_link\">",
"     \"Pruritus: Overview of management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of therapies, both systemic and topical, have been used for the treatment of post-burn pruritus. Proof of efficacy is primarily anecdotal as high quality randomized trials have not been performed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/55,58\">",
"     55,58",
"    </a>",
"    ]. Systemic first-line treatment for post-burn pruritus consists of H1 and H2 antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    ), but none has provided complete relief. Other systemic agents that may prove helpful include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/25/19862?source=see_link\">",
"     cyproheptadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , and tricyclic antidepressants (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"     doxepin",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Topical treatments, which may provide relief of pruritus, include [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/5,55,58-60\">",
"     5,55,58-60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Aloe vera",
"     </li>",
"     <li>",
"      Vaseline based creams",
"     </li>",
"     <li>",
"      Cocoa butter",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13316?source=see_link\">",
"       Mineral oil",
"      </a>",
"     </li>",
"     <li>",
"      Hydrogel sheets (eg, Tegagel, Vigilon, FlexiGel)",
"     </li>",
"     <li>",
"      Topical glucocorticoids",
"     </li>",
"     <li>",
"      Colloidal oatmeal in liquid paraffin",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/14/23777?source=see_link\">",
"       UNNA boot",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/32/14852?source=see_link\">",
"       glycerin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/53/15187?source=see_link\">",
"       zinc oxide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/11/33969?source=see_link\">",
"       calamine lotion",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      EMLA, which is a mixture of local anesthetics",
"     </li>",
"     <li>",
"      Topical",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/51/32560?source=see_link\">",
"       doxepin",
"      </a>",
"     </li>",
"     <li>",
"      Silicone gel sheeting",
"     </li>",
"     <li>",
"      Compression garments",
"     </li>",
"     <li>",
"      Massage therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The role of topical glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    ) varies importantly with the stage of the burn. These agents can be applied to reepithelialized wounds. In contrast, topical glucocorticoids are",
"    <strong>",
"     not",
"    </strong>",
"    used on unhealed burns, since they can lead to thinning of the healing skin, infection, and systemic absorption.",
"   </p>",
"   <p>",
"    Topical agents high in lanolin should be",
"    <strong>",
"     avoided",
"    </strong>",
"    , since they can worsen pruritus [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other therapies that have been evaluated for the treatment of pruritus in burn patients include transcutaneous electrical nerve stimulation (TENS) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/59,62\">",
"     59,62",
"    </a>",
"    ] and pulsed dye laser [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. TENS is a treatment option in patients who fail the above therapies. However, in clinical practice, TENS is rarely used as a treatment for pruritus and is experimental. Further assessment in clinical trials is needed before this can be a recommended treatment.",
"   </p>",
"   <p>",
"    Conventional pulsed dye laser (585 nm) treatment, applied three times at monthly intervals, was evaluated in a study of 38 patients in whom the area of scar was divided randomly into treatment and control [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/63\">",
"     63",
"    </a>",
"    ]. Pruritus was evaluated on a score of 1 to 10 in adults and by signs of excoriation in children. Pruritus was significantly reduced following one laser treatment in comparison to the level of pruritus prior to treatment. Although pruritus was reduced in both treated and untreated areas of the burn, the improvement was significantly greater in the treated area at 1, 6, and 12 months. Other studies have reported alleviation of pruritus and burning sensation following a single laser treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. A variety of ablative and nonablative lasers and pulse dye therapies are experimental for the management of the burn wound management. While these results are promising, this approach is still experimental, and further assessment in clinical trials is needed before this can be a recommended treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11194530\">",
"    <span class=\"h1\">",
"     LOCAL TREATMENT OF BURN SCARS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertrophic scarring is thought to be likely in any burn victim in whom complete or near complete reepithelialization takes longer than three to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/67\">",
"     67",
"    </a>",
"    ]. As a result, burn patients should be promptly referred to a surgeon experienced in burn care at the first sign of hypertrophic scarring or if the wound fails to begin reepithelialization by two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early application of moisturizing agents (as listed in the preceding section), silicon sheeting [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/60\">",
"     60",
"    </a>",
"    ], and massage is generally advocated for healed burns, particularly those that presented initially as deep injuries or those that show signs of delayed healing [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/69\">",
"     69",
"    </a>",
"    ]. The role of pressure garment therapy is less clear. Pressure garments are routinely advocated by most burn centers, although there is no definitive&nbsp;evidence of efficacy. A review of six high quality clinical trials of pressure garment therapy found scar height was statistically significantly reduced, although this measurable difference is of questionable clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29225/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21594261\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with superficial partial-thickness burns, or deeper burns prior to excision and skin grafting, there is no consensus on which topical antimicrobial agents and dressings provide the best burn wound coverage to prevent or control infection. Minor (eg, sunburn) and superficial partial-thickness burns with an intact epithelium do not require treatment with a topical antimicrobial agent or dressing.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest using a topical antimicrobial agent or bismuth-impregnated petroleum based gauze (eg, Xeroform) as the initial burn wound coverage for superficial partial-thickness burns devoid of epithelium and deeper burns (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These agents provide a moist environment conducive to wound healing. Commonly used topical antimicrobial agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10964?source=see_link\">",
"       silver sulfadiazine",
"      </a>",
"      , combination antibiotics, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      . In the absence of high quality data comparing agents, the choice can be made based on cost, availability, and provider familiarity. Silver",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/41/20118?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      with cerium or alone, and povidone-iodine are contraindicated in newborns, pregnancy, and lactation. (See",
"      <a class=\"local\" href=\"#H21593928\">",
"       'Topical antimicrobial agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using fine mesh gauze with a topical antimicrobial agent, as the dressing of choice for most superficial partial-thickness burns (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There is no consensus on which dressing provides the best coverage. (See",
"      <a class=\"local\" href=\"#H21593997\">",
"       'Dressings'",
"      </a>",
"      above.) In the absence of high quality data comparing other types of dressings (eg, hydrocolloid, silver containing dressings, biosynthetic, and biologic dressings), the choice can be made based on cost, availability, phase of burn wound healing, frequency of dressing changes, and provider familiarity.",
"     </li>",
"     <li>",
"      No clear evidence exists to support any specific approach to the frequency of dressing changes, which range from twice daily to weekly. Dressing changes should be frequent enough to control exudate, but not so frequent as to interfere with wound reepithelialization. It appears best to change dressings whenever they become soaked with excessive exudate or other fluids, or if there are signs of infection. Topical antibiotics should be removed gently with dressing changes; scrubbing and sharp debridement is not necessary and may hinder healing. (See",
"      <a class=\"local\" href=\"#H21593997\">",
"       'Dressings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of oral medications and topical agents are used to treat post-burn pruritus. Systemic first-line treatment for post-burn pruritus consists of H1 and H2 antihistamines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36390?source=see_link\">",
"       cetirizine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      ), but none has provided complete relief. Topical agents include aloe vera, vaseline based products, and cocoa butter. Proof of efficacy is primarily anecdotal as high quality randomized trials have not been performed. (See",
"      <a class=\"local\" href=\"#H11194486\">",
"       'Local treatment of pruritus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Burn patients should be referred to a surgeon with expertise in burn care if complete or near complete reepithelialization takes longer than three to four weeks as well as at the first sign of hypertrophic scarring or if the wound. (See",
"      <a class=\"local\" href=\"#H11194530\">",
"       'Local treatment of burn scars'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519352517\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Hans-Oliver Rennekampff, who contributed to an earlier version of this topic review",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/1\">",
"      Wasiak J, Cleland H, Campbell F. Dressings for superficial and partial thickness burns. Cochrane Database Syst Rev 2008; :CD002106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/2\">",
"      Hoogewerf CJ, Van Baar ME, Hop MJ, et al. Topical treatment for facial burns. Cochrane Database Syst Rev 2013; 1:CD008058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/3\">",
"      Hunter GR, Chang FC. Outpatient burns: a prospective study. J Trauma 1976; 16:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/4\">",
"      Miller SF. Outpatient management of minor burns. Am Fam Physician 1977; 16:167.",
"     </a>",
"    </li>",
"    <li>",
"     Hartford CE, Kealey GP. Care of outpatient burns. In: Total Burn Care, Third edition, Herndon, DN (Eds), 2007. p.67.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/6\">",
"      Klasen HJ. A review on the nonoperative removal of necrotic tissue from burn wounds. Burns 2000; 26:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/7\">",
"      Ozcan C, Erg&uuml;n O, Celik A, et al. Enzymatic debridement of burn wound with collagenase in children with partial-thickness burns. Burns 2002; 28:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/8\">",
"      Koller J, Bukovcan P, Ors&aacute;g M, et al. Enzymatic necrolysis of acute deep burns--report of preliminary results with 22 patients. Acta Chir Plast 2008; 50:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/9\">",
"      Sargent RL. Management of blisters in the partial-thickness burn: an integrative research review. J Burn Care Res 2006; 27:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/10\">",
"      D'Avignon LC, Saffle JR, Chung KK, Cancio LC. Prevention and management of infections associated with burns in the combat casualty. J Trauma 2008; 64:S277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/11\">",
"      Palmieri TL, Greenhalgh DG. Topical treatment of pediatric patients with burns: a practical guide. Am J Clin Dermatol 2002; 3:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/12\">",
"      Hussain S, Ferguson C. Best evidence topic report. Silver sulphadiazine cream in burns. Emerg Med J 2006; 23:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/13\">",
"      Schonfeld N. Outpatient management of burns in children. Pediatr Emerg Care 1990; 6:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/14\">",
"      Fox CL Jr, Monafo WW Jr, Ayvazian VH, et al. Topical chemotherapy for burns using cerium salts and silver sulfadiazine. Surg Gynecol Obstet 1977; 144:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/15\">",
"      de Gracia CG. An open study comparing topical silver sulfadiazine and topical silver sulfadiazine-cerium nitrate in the treatment of moderate and severe burns. Burns 2001; 27:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/16\">",
"      Ross DA, Phipps AJ, Clarke JA. The use of cerium nitrate-silver sulphadiazine as a topical burns dressing. Br J Plast Surg 1993; 46:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/17\">",
"      Garner JP, Heppell PS. Cerium nitrate in the management of burns. Burns 2005; 31:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/18\">",
"      Munster AM, Helvig E, Rowland S. Cerium nitrate-silver sulfadiazine cream in the treatment of burns: a prospective evaluation. Surgery 1980; 88:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/19\">",
"      Bowser BH, Caldwell FT, Cone JB, et al. A prospective analysis of silver sulfadiazine with and without cerium nitrate as a topical agent in the treatment of severely burned children. J Trauma 1981; 21:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/20\">",
"      Barillo DJ. Using mafenide acetate in acute and chronic wounds. Ostomy Wound Manage 2002; Suppl:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/21\">",
"      Kucan JO, Smoot EC. Five percent mafenide acetate solution in the treatment of thermal injuries. J Burn Care Rehabil 1993; 14:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/22\">",
"      Norman D. The use of povidone-iodine in superficial partial-thickness burns. Br J Nurs 2003; 12:S30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/23\">",
"      Homann HH, Rosbach O, Moll W, et al. A liposome hydrogel with polyvinyl-pyrrolidone iodine in the local treatment of partial-thickness burn wounds. Ann Plast Surg 2007; 59:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/24\">",
"      Malpass KG, Snelling CF, Tron V. Comparison of donor-site healing under Xeroform and Jelonet dressings: unexpected findings. Plast Reconstr Surg 2003; 112:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/25\">",
"      Hansbrough W, Dor&eacute; C, Hansbrough JF. Management of skin-grafted burn wounds with Xeroform and layers of dry coarse-mesh gauze dressing results in excellent graft take and minimal nursing time. J Burn Care Rehabil 1995; 16:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/26\">",
"      Agostinho AM, Hartman A, Lipp C, et al. An in vitro model for the growth and analysis of chronic wound MRSA biofilms. J Appl Microbiol 2011; 111:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/27\">",
"      Neely AN, Gardner J, Durkee P, et al. Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? J Burn Care Res 2009; 30:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/28\">",
"      Cooper ML, Boyce ST, Hansbrough JF, et al. Cytotoxicity to cultured human keratinocytes of topical antimicrobial agents. J Surg Res 1990; 48:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/29\">",
"      Wyatt D, McGowan DN, Najarian MP. Comparison of a hydrocolloid dressing and silver sulfadiazine cream in the outpatient management of second-degree burns. J Trauma 1990; 30:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/30\">",
"      Nadworny PL, Wang J, Tredget EE, Burrell RE. Anti-inflammatory activity of nanocrystalline silver-derived solutions in porcine contact dermatitis. J Inflamm (Lond) 2010; 7:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/31\">",
"      Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystalline silver in the management of burns. Burns 2004; 30 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/32\">",
"      Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H. Topical silver for preventing wound infection. Cochrane Database Syst Rev 2010; :CD006478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/33\">",
"      Gravante G, Caruso R, Sorge R, et al. Nanocrystalline silver: a systematic review of randomized trials conducted on burned patients and an evidence-based assessment of potential advantages over older silver formulations. Ann Plast Surg 2009; 63:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/34\">",
"      Innes ME, Umraw N, Fish JS, et al. The use of silver coated dressings on donor site wounds: a prospective, controlled matched pair study. Burns 2001; 27:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/35\">",
"      Argirova M, Hadjiski O, Victorova A. Acticoat versus Allevyn as a split-thickness skin graft donor-site dressing: a prospective comparative study. Ann Plast Surg 2007; 59:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/36\">",
"      Kesting MR, Wolff KD, Hohlweg-Majert B, Steinstraesser L. The role of allogenic amniotic membrane in burn treatment. J Burn Care Res 2008; 29:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/37\">",
"      Ramakrishnan KM, Jayaraman V. Management of partial-thickness burn wounds by amniotic membrane: a cost-effective treatment in developing countries. Burns 1997; 23 Suppl 1:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/38\">",
"      Pham C, Greenwood J, Cleland H, et al. Bioengineered skin substitutes for the management of burns: a systematic review. Burns 2007; 33:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/39\">",
"      Whitaker IS, Prowse S, Potokar TS. A critical evaluation of the use of Biobrane as a biologic skin substitute: a versatile tool for the plastic and reconstructive surgeon. Ann Plast Surg 2008; 60:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/40\">",
"      McHugh TP, Robson MC, Heggers JP, et al. Therapeutic efficacy of Biobrane in partial- and full-thickness thermal injury. Surgery 1986; 100:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/41\">",
"      Peck MD, Kessler M, Meyer AA, Bonham Morris PA. A trial of the effectiveness of artificial dermis in the treatment of patients with burns greater than 45% total body surface area. J Trauma 2002; 52:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/42\">",
"      Smith DJ, McHugh TP, Phillips LG, et al. Biosynthetic compound dressings--management of hand burns. Burns Incl Therm Inj 1988; 14:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/43\">",
"      Frame JD, Taweepoke P, Moieman N, Rylah L. Immediate fascial flap reconstruction of joints and use of Biobrane in the burned limb. Burns 1990; 16:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/44\">",
"      Malic CC, Karoo RO, Austin O, Phipps A. A glove to sock dressing. Burns 2005; 31:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/45\">",
"      Lang EM, Eiberg CA, Brandis M, Stark GB. Biobrane in the treatment of burn and scald injuries in children. Ann Plast Surg 2005; 55:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/46\">",
"      Schwarze H, K&uuml;ntscher M, Uhlig C, et al. Suprathel, a new skin substitute, in the management of partial-thickness burn wounds: results of a clinical study. Ann Plast Surg 2008; 60:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/47\">",
"      Woodroof EA. The search for an ideal temporary skin substitute: AWBAT. Eplasty 2009; 9:e10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/48\">",
"      Vandenberg VB. AWBAT: early clinical experience. Eplasty 2010; 10:e23.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health Clinical Trials database. Multi-Center, Prospective, Randomized, Comparison of AWBAT&trade;-D vs. Xeroform&trade; or Glucan II&trade; for Treatment of Donor Sites in Burn Surgery (AWBAT-D). ClinicalTrials.gov Identifier NCT00964470. Aubrey Inc. 2009	 file://www.clinicaltrials.gov/ (Accessed on July 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/50\">",
"      Delatte SJ, Evans J, Hebra A, et al. Effectiveness of beta-glucan collagen for treatment of partial-thickness burns in children. J Pediatr Surg 2001; 36:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/51\">",
"      Piatkowski A, Drummer N, Andriessen A, et al. Randomized controlled single center study comparing a polyhexanide containing bio-cellulose dressing with silver sulfadiazine cream in partial-thickness dermal burns. Burns 2011; 37:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/52\">",
"      Wai RT. Use of glycerol-preserved skin in plastic surgery. Burns 1994; 20 Suppl 1:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/53\">",
"      Song IC, Bromberg BE, Mohn MP, Koehnlein E. Heterografts as biological dressings for large skin wounds. Surgery 1966; 59:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/54\">",
"      Elliott RA Jr, Hoehn JG. Use of commercial porcine skin for wound dressings. Plast Reconstr Surg 1973; 52:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/55\">",
"      Goutos I, Dziewulski P, Richardson PM. Pruritus in burns: review article. J Burn Care Res 2009; 30:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/56\">",
"      O'Donoghue M, Tharp MD. Antihistamines and their role as antipruritics. Dermatol Ther 2005; 18:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/57\">",
"      Van Loey NE, Bremer M, Faber AW, et al. Itching following burns: epidemiology and predictors. Br J Dermatol 2008; 158:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/58\">",
"      Bell PL, Gabriel V. Evidence based review for the treatment of post-burn pruritus. J Burn Care Res 2009; 30:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/59\">",
"      Whitaker C. The use of TENS for pruritus relief in the burns patient: an individual case report. J Burn Care Rehabil 2001; 22:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/60\">",
"      Li-Tsang CW, Lau JC, Choi J, et al. A prospective randomized clinical trial to investigate the effect of silicone gel sheeting (Cica-Care) on post-traumatic hypertrophic scar among the Chinese population. Burns 2006; 32:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/61\">",
"      Baxter CR. Management of burn wounds. Dermatol Clin 1993; 11:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/62\">",
"      Hettrick HH, O'Brien K, Laznick H, et al. Effect of transcutaneous electrical nerve stimulation for the management of burn pruritus: a pilot study. J Burn Care Rehabil 2004; 25:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/63\">",
"      Allison KP, Kiernan MN, Waters RA, Clement RM. Pulsed dye laser treatment of burn scars. Alleviation or irritation? Burns 2003; 29:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/64\">",
"      Parrett BM, Donelan MB. Pulsed dye laser in burn scars: current concepts and future directions. Burns 2010; 36:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/65\">",
"      Kono T, Er&ccedil;&ouml;&ccedil;en AR, Nakazawa H, Nozaki M. Treatment of hypertrophic scars using a long-pulsed dye laser with cryogen-spray cooling. Ann Plast Surg 2005; 54:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/66\">",
"      Alster TS, Nanni CA. Pulsed dye laser treatment of hypertrophic burn scars. Plast Reconstr Surg 1998; 102:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/67\">",
"      Bloemen MC, van der Veer WM, Ulrich MM, et al. Prevention and curative management of hypertrophic scar formation. Burns 2009; 35:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/68\">",
"      Luce EA. The acute and subacute management of the burned hand. Clin Plast Surg 2000; 27:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/69\">",
"      Carr-Collins JA. Pressure techniques for the prevention of hypertrophic scar. Clin Plast Surg 1992; 19:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29225/abstract/70\">",
"      Anzarut A, Olson J, Singh P, et al. The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis. J Plast Reconstr Aesthet Surg 2009; 62:77.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13509 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29225=[""].join("\n");
var outline_f28_34_29225=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21594261\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21593871\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21593914\">",
"      LOCAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21593921\">",
"      Cleansing and debridement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1054478388\">",
"      - Burn blisters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21593928\">",
"      Topical antimicrobial agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21593935\">",
"      - Silver sulfadiazine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21593943\">",
"      Cerium plus SSD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21593951\">",
"      - Combination antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21593959\">",
"      - Chlorhexidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21593967\">",
"      - Mafenide acetate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21593975\">",
"      - Povidone-iodine ointment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21593990\">",
"      - Bismuth-impregnated petroleum gauze",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4324758\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21593997\">",
"      Dressings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21594004\">",
"      - Compresses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594011\">",
"      Fine mesh gauze",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594019\">",
"      Hydrocolloid dressings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594027\">",
"      Silver containing dressings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21594043\">",
"      - Biosynthetic dressings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594051\">",
"      Biobrane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594058\">",
"      Biobrane-like",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H102063607\">",
"      Polyhexanide containing bio-cellulose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21594072\">",
"      - Biologic dressings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594080\">",
"      Allogeneic skin grafts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594087\">",
"      Human amnion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H21594094\">",
"      Skin xenografts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11194486\">",
"      LOCAL TREATMENT OF PRURITUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11194530\">",
"      LOCAL TREATMENT OF BURN SCARS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21594261\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H519352517\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/13509\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/13509|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/8/14477\" title=\"table 1\">",
"      Antimicrobial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44201?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18409?source=related_link\">",
"      Primary operative management of hand burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6058?source=related_link\">",
"      Pruritus: Overview of management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/38/37479?source=related_link\">",
"      Treatment of minor thermal burns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_34_29226="Management of asthma during pregnancy";
var content_f28_34_29226=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of asthma during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29226/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29226/contributors\">",
"     Michael Schatz, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29226/contributors\">",
"     Steven E Weinberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29226/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29226/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29226/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/34/29226/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/34/29226/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/34/29226/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma is one of the most common medical conditions encountered during pregnancy, occurring in 3 to 8 percent of pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Pregnancy may be associated with changes in the course of asthma, and asthma may affect the outcome of pregnancy.",
"   </p>",
"   <p>",
"    The management of asthma in pregnancy, including general management issues, the safety data for specific asthma medications, and recommended pharmacotherapy for acute and chronic asthma in pregnancy, is reviewed here. The physiology and clinical course of asthma in pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=see_link\">",
"     \"Physiology and clinical course of asthma in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MEDICATIONS IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two important considerations arise with the use of any medication in pregnancy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Are there potential adverse effects of the medication on the developing fetus?",
"     </li>",
"     <li>",
"      Does pregnancy alter the metabolism or the bioavailability of the medication?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Potential adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications administered during pregnancy have been associated with an increased risk of several adverse outcomes, which are not independent, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Miscarriage",
"     </li>",
"     <li>",
"      Fetal death",
"     </li>",
"     <li>",
"      Congenital malformation (especially first trimester exposure)",
"     </li>",
"     <li>",
"      Reduced fetal growth",
"     </li>",
"     <li>",
"      Impaired function of developing organs, such as the central nervous system or kidney",
"     </li>",
"     <li>",
"      Reduced uteroplacental blood flow",
"     </li>",
"     <li>",
"      Increased risk of preterm delivery",
"     </li>",
"     <li>",
"      Drug related side effects in the newborn",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Information about potential adverse effects must be interpreted with an understanding that the baseline frequency of complications in pregnancy is relatively high, even in the absence of asthma or other disorders. In the United States, major congenital anomalies occur in 3 percent of live&ndash;born infants; miscarriages, in 10 to 15 percent of clinically diagnosed pregnancies; 12 percent of births are preterm; one in 200 pregnancies end in stillbirth; and mental retardation (IQ &lt;70) is diagnosed in 1 to 2 percent of",
"    <span class=\"nowrap\">",
"     children/adults",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a small but significant increase in complications of pregnancy in asthmatic women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/10\">",
"     10",
"    </a>",
"    ]. The largest study reported to date suggests that asthmatic patients, on average, have a 15 to 20 percent increased risk of perinatal mortality, preeclampsia, preterm delivery, or low birth weight infants compared to non-asthmatic women, and that patients with more severe asthma have a 30 to 100 percent increased risk (",
"    <a class=\"graphic graphic_table graphicRef59809 \" href=\"UTD.htm?19/27/19899\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/10\">",
"     10",
"    </a>",
"    ]. This study did not find an increased risk of congenital malformations in the infants of asthmatic mothers.",
"   </p>",
"   <p>",
"    Relatively few drugs have been proven harmful in pregnancy and less than 1 percent of congenital malformations can be attributed to drugs; however, statistical and ethical considerations make it unlikely that any drug will ever be \"proven safe\" [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Although unnecessary use of medication during pregnancy should be avoided, the risks of untreated disease must be considered in parallel. Fortunately, a relatively large body of evidence supports the use of several important therapies for asthma during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Assessing risk of medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk associated with use of a specific medication in pregnancy can be assessed using several sources of information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human data &ndash; Human data exist in the form of case reports, cohort studies, and case-control studies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/12\">",
"       12",
"      </a>",
"      ]. Case reports, in which an exposure and an outcome are presented, provide limited data regarding cause and effect. Cohort studies prospectively evaluate exposed and non-exposed populations to determine outcome, and case-control studies retrospectively evaluate affected and non-affected subjects for whether or not they were exposed.",
"      <br/>",
"      <br/>",
"      Negative cohort studies are reassuring. However, they rarely include sufficient numbers of exposed individuals to rule out a small (but important) increase in adverse pregnancy outcome, particularly when dealing with outcomes such as specific malformations, the most common of which may only occur in 3 per 1000 births [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Positive cohort or case-control studies do not prove causation and generally suggest hypotheses requiring independent confirmation [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/12,14,15\">",
"       12,14,15",
"      </a>",
"      ]. Nonetheless, when effective alternatives are available, drugs that have been implicated as causing adverse effects in cohort or case-control studies should be avoided.",
"     </li>",
"     <li>",
"      Animal data &ndash; Animal teratology experiments can be useful in evaluating human drug risks, although animals differ from humans in a number of ways. Animal studies are designed to maximize the response of the system to potential toxic effects of the test agent by using large doses [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It is believed that a testing scheme using appropriate doses in at least two species, one of which is a non-rodent, is sufficient to raise suspicion of human developmental risk. There are, in fact, no known human developmental toxicants that would not have been identified in this manner [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/11\">",
"       11",
"      </a>",
"      ]. Thus, if an agent is appropriately tested in animals and found not to be a developmental toxicant, its potential for human developmental toxicity is low [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/16\">",
"       16",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      By comparison, positive data in animal studies are not as useful because it is frequently not possible to know whether species differences, the clinically irrelevant high doses used, or maternal toxicity was responsible for the adverse effects on the offspring [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      FDA categories &ndash; The United States Food and Drug Administration established five categories to describe a drug's potential for causing adverse effects during pregnancy (",
"      <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"       table 2",
"      </a>",
"      ) and mandated that newly approved drugs introduced after November 1, 1980 be classified into one of these categories in the package insert [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/15\">",
"       15",
"      </a>",
"      ]. The categories are based on the results of animal studies, human data, and consideration of whether the benefit of the drug's use during pregnancy outweighs the risk.",
"      <br/>",
"      <br/>",
"      No asthma or allergy medication labeled to date meets the requirements for category A. Most category B drugs are labeled as such because of reassuring animal studies without \"adequate and controlled\" human data. As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      is classified as a category B drug based on reassuring data from the population-based Swedish Medical Birth Registry [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/17\">",
"       17",
"      </a>",
"      ]. One may wish to choose class B versus C drugs among equally effective alternatives due to the reassuring animal studies. Category D provides a strong relative contraindication to use in pregnancy, and category X drugs should not be used. Over the years, increasing dissatisfaction has arisen regarding the clinical usefulness of these categories [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/18\">",
"       18",
"      </a>",
"      ], and the FDA is currently developing a new, more descriptive system of pregnancy labeling [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other considerations &ndash; A topical medication would appear to be preferable to a systemic one due to reduced likelihood of fetal penetration. An older medication with a \"track record\" may be preferable to a newer one. Finally, absolute and relative efficacy must also be considered in the choice of a medication for use during pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Altered pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of altered pharmacokinetics of medications during pregnancy is relevant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Methylxanthines'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENERAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma may improve, worsen, or remain unchanged in severity during pregnancy. The potential mechanisms involved and clinical implications of these findings are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=see_link\">",
"     \"Physiology and clinical course of asthma in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two primary goals of asthma management, ie, prevention of acute episodes and optimization of ongoing pulmonary function, are unchanged in the setting of pregnancy, and should serve to maximize both maternal and fetal health [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/20\">",
"     20",
"    </a>",
"    ]. Prevention of acute episodes should prevent potentially harmful acute hypoxia, hypocapnia, alkalosis, and dehydration. Optimization of chronic maternal pulmonary function should reduce the potential for chronic hypoxia, maternal symptoms, as well as the likelihood of acute episodes.",
"   </p>",
"   <p>",
"    Careful follow-up by clinicians experienced in managing asthma is essential. Asthmatic women requiring regular medication should be evaluated at least monthly. All pregnant patients should have ready access to their clinician should their symptoms change or increase. It is also important that effective communication exists among the clinician managing the asthma, the patient, and the obstetrician.",
"   </p>",
"   <p>",
"    The Expert Panel Report of the Working Group on Asthma and Pregnancy stressed the following four important components of effective therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Objective monitoring of maternal lung function and fetal well&ndash;being as a guide to therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H6#H6\">",
"       \"An overview of asthma management\", section on 'Monitoring patients with asthma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"       \"Peak expiratory flow rate monitoring in asthma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"       \"Overview of fetal assessment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Proper control of environmental and other triggers for asthma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"       \"Trigger control to enhance asthma management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patient education (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"       \"What do patients need to know about their asthma?\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pharmacologic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Monitoring lung function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diminished pulmonary function during pregnancy is associated with adverse perinatal outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]; it is therefore important to monitor pulmonary function in patients with asthma. Normal pregnancy-related changes in pulmonary function are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=see_link\">",
"     \"Respiratory tract changes during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Asthmatic symptoms are often greatest at night, leading to nocturnal awakening, or when waking up in the morning. Functional assessment by the patient during times of worsening symptoms may provide a more accurate reflection of the patient's condition than spirometric measurements at the clinician's office.",
"   </p>",
"   <p>",
"    Although monitoring pulmonary function using spirometry can be useful, measurement of peak expiratory flow rate (PEFR), or forced expiratory volume in one second (FEV1), using a portable device offers the advantages of less expense and greater ease of serial measurements at home. Ideally, patients with asthma should measure their PEFR twice a day: upon awakening and approximately 12 hours later. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional issue for pregnant women with asthma is the difficulty differentiating an exacerbation of asthma symptoms from the normal sensation of dyspnea experienced during pregnancy. The presence of cough and wheezing suggests asthma. Objective information can also be obtained by measurement of the PEFR or FEV1; reductions in either suggest an asthma exacerbation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39446?source=see_link\">",
"     \"Dyspnea during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link&amp;anchor=H6#H6\">",
"     \"Diagnosis of asthma in adolescents and adults\", section on 'Pulmonary function testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Smoking cessation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical for the pregnant asthmatic woman to discontinue smoking during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/24\">",
"     24",
"    </a>",
"    ]. First, smoking may predispose the patient to asthma exacerbations, bronchitis or sinusitis, and therefore necessitate an increased need for medication [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/25\">",
"     25",
"    </a>",
"    ]. Second, the increased perinatal morbidity attributed to smoking may be additive to the baseline risk conferred by uncontrolled maternal asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=see_link&amp;anchor=H19#H19\">",
"     \"Smoking and pregnancy\", section on 'Smoking cessation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Environmental control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of environmental triggers is an important component of the management of asthma during pregnancy. This includes avoiding exposure to allergens and to nonspecific airway irritants, such as tobacco smoke, dust, and environmental pollutants. Particular allergens of concern are dander from pets and antigens from household dust mites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principles of patient education are generally similar for the pregnant and nonpregnant patient with asthma. Important issues include early recognition of signs and symptoms of an asthma exacerbation, avoidance of precipitating factors, correct use of medications, and development of a treatment plan for acute exacerbations.",
"   </p>",
"   <p>",
"    The primary issues that are specific for pregnancy are education about the interrelationships between asthma and pregnancy and the safety of asthma medications during pregnancy. The clinician should clearly explain that it is safer for pregnant women with asthma to take asthma medications than to have ongoing symptoms or exacerbations of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/22,26\">",
"     22,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asthma may add to the stress of normal pregnancy, and the stress of pregnancy may aggravate asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/27\">",
"     27",
"    </a>",
"    ]. It is important that anxiety regarding asthma and its impact on pregnancy be reduced by giving women the opportunity to express their concerns and then providing appropriate information [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/28\">",
"     28",
"    </a>",
"    ]. Women should be reassured that safe and adequate asthma treatment is possible during pregnancy and that good asthma control can help to minimize the risk of complications. Educational material for pregnant asthmatic patients has been published [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/29\">",
"     29",
"    </a>",
"    ]. General and pregnancy-specific patient information is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"     \"What do patients need to know about their asthma?\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=see_link\">",
"     \"Patient information: Asthma and pregnancy (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SAFETY OF SPECIFIC MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with many of the medications used to treat asthma suggests minimal or no known adverse effects for their use during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/1-3,7,14,17,21,30-35\">",
"     1-3,7,14,17,21,30-35",
"    </a>",
"    ]. Most drugs used in the treatment of asthma fall into categories B or C. Additional information and links to national databases for reproductive teratology are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=see_link\">",
"     \"Principles of teratology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cohort studies are reassuring and show a lack of adverse effects on human pregnancy outcomes with the following drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       Albuterol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/14,31\">",
"       14,31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"       Metaproterenol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       Theophylline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/14,30,37\">",
"       14,30,37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"       Cromolyn sodium",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/30,38\">",
"       30,38",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       Beclomethasone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/30,32\">",
"       30,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       Budesonide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/17,39\">",
"       17,39",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, data regarding the use of oral glucocorticoids during pregnancy have not been totally reassuring. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Oral/Systemic'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For a number of asthma medications, there are minimal or no published human data. These include drugs with reassuring animal studies (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    ) and those with non-reassuring animal studies (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    ). Each of the major classes of medication currently in use for asthma is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369937555\">",
"    <span class=\"h2\">",
"     Inhaled beta-adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of reports provide reassurance regarding the use of inhaled beta-agonists during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/14,31,36\">",
"     14,31,36",
"    </a>",
"    ]. Clinical experience is greater with the older agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ) than with the newer ones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     salmeterol",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Short-acting beta-adrenergic agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The short-acting, selective beta-2 adrenergic bronchodilators (SABAs) are used to provide quick relief of asthma symptoms and appear to be relatively safe during pregnancy.",
"   </p>",
"   <p>",
"    In animal studies, some of the SABAs have been teratogenic when given in high doses, but there has been no clear evidence of teratogenicity in humans. In a study of 259 pregnant asthmatic women, for example, no adverse effects on the fetus were noted with the use of an inhaled SABA (primarily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"     metaproterenol",
"    </a>",
"    ) when compared with control subjects, even though 180 of the women used these agents during the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/36\">",
"     36",
"    </a>",
"    ]. However, in a case-control study, a small increased risk of gastroschisis was reported among infants exposed in utero to bronchodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/40\">",
"     40",
"    </a>",
"    ]. An association with cardiac defects was noted in a cohort study that examined the effect of exposure to bronchodilator therapy during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/41\">",
"     41",
"    </a>",
"    ]. One problem with assessing the consequences of bronchodilator use in pregnancy is confounding introduced by indication; SABA use is a marker for poorly-controlled asthma and more frequent exacerbations, which may independently contribute to the development of congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic beta&ndash;adrenergic agonists have also been used as tocolytic agents (ie, as inhibitors of uterine contraction) in the setting of premature labor. When given for this indication, the major maternal concern is resultant hyperglycemia. Prenatally exposed neonates have been found to have tachycardia, hypoglycemia, and tremor; these effects in the neonate, however, have been treatable, are reversible, and are therefore not considered a contraindication to use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=see_link&amp;anchor=H7#H7\">",
"     \"Inhibition of acute preterm labor\", section on 'Beta-adrenergic receptor agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is preliminary evidence that the use of SABAs during pregnancy could have other beneficial effects for some asthmatic women. In one nested case-control cohort study [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/42\">",
"     42",
"    </a>",
"    ], SABA use during pregnancy was associated with a significantly reduced risk of gestational hypertension (ie, hypertension without proteinuria), although the risk of overt preeclampsia (ie, hypertension with proteinuria) was not affected. Further studies are needed to establish causality, since nonasthmatic pregnant controls were not included in this observational study and residual confounding could therefore not be excluded. Inhaled SABAs, however, can reduce diastolic blood pressure in non-pregnant patients, a finding that could provide a plausible biologic mechanism for this effect [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/43\">",
"     43",
"    </a>",
"    ]. These findings are preliminary; clinicians should continue with the goal of minimizing use of SABAs in both pregnant and non-pregnant patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H369937512\">",
"    <span class=\"h3\">",
"     Long-acting beta-adrenergic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience with inhalation of the long-acting, selective beta-2 adrenergic bronchodilators (LABAs) during pregnancy is less extensive than with the short-acting bronchodilators (SABAs).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     Salmeterol",
"    </a>",
"    is not expected to increase the risk of congenital anomalies, based on data from animal studies and limited human experience [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/44\">",
"     44",
"    </a>",
"    ]. Animal studies are also reassuring for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    , although data from human pregnancies is very limited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these findings, continuation of a LABA during pregnancy is reasonable if a LABA has been needed to achieve asthma control before pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications for LABA therapy in asthma, the importance of combining LABA therapy with an inhaled glucocorticoid, and the controversy regarding the safety of LABA therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\", section on 'Medium-dose inhaled GCs plus a LABA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of severe asthma in adolescents and adults\", section on 'Combination inhaled GC/LABA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link&amp;anchor=H4#H4\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\", section on 'Long-acting beta agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern has been raised that the alpha&ndash;adrenergic effects of epinephrine might cause vasoconstriction in the uteroplacental circulation. Although there is no objective evidence that this is a problem in humans, the Working Group on Pregnancy and Asthma recommended that epinephrine generally be avoided during pregnancy except in the setting of anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21\">",
"     21",
"    </a>",
"    ]. For the rare patient who requires use of a systemic beta-agonist to treat asthma, subcutaneous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"     terbutaline",
"    </a>",
"    is a reasonable choice (",
"    <a class=\"graphic graphic_table graphicRef67529 \" href=\"UTD.htm?35/32/36364\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of their importance in the treatment of a variety of inflammatory conditions, systemic glucocorticoids have been used fairly extensively during pregnancy. Similarly, inhaled glucocorticoids are frequently used for asthma control during pregnancy, although randomized trials have not been performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Oral/Systemic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several potential areas of concern have been raised with the use of systemic glucocorticoids: congenital malformations (primarily cleft palate), preeclampsia, gestational diabetes, low birth weight, and neonatal adrenal insufficiency. A few studies exist in which systemic glucocorticoids were used for the management of asthma during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/14,30,31,49-51\">",
"     14,30,31,49-51",
"    </a>",
"    ]. Some showed a slightly increased risk of prematurity and a slightly higher risk of low birth weight (less than 2500 g) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/14,31,50\">",
"     14,31,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital malformations &ndash; Data from animal studies in several species suggest that high dose systemic glucocorticoids may lead to cleft palate. Palatal closure is usually complete by the 12th week of pregnancy, so potential risk would be limited to administration during the first trimester. Human studies are less concerning but a possible effect cannot be dismissed. A meta-analysis was performed of (1) cohort studies that evaluated the relationship between first trimester maternal oral glucocorticoid use and total congenital malformations and (2) case-control studies evaluating the relationship between first trimester maternal oral glucocorticoid use and oral clefts (cleft lip with or without cleft palate) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/52\">",
"       52",
"      </a>",
"      ]. No definite increased association of systemic glucocorticoids with total malformations was identified from the six cohort studies (summary odds ratio = 1.45, 95% CI of 0.80, 2.60). However, a meta-analysis of the four case-control studies revealed an association of oral clefts in infants of oral glucocorticoid-treated mothers (summary odds ratio = 3.35, 95% CI of 1.97, 5.69).",
"      <br/>",
"      <br/>",
"      In a cohort study, the outcomes of 311 pregnancies with systemic glucocorticoid use for various indications during the first trimester were compared with those of 790 controls without teratogenic exposure; the rate of major anomalies did not differ significantly between the groups [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/53\">",
"       53",
"      </a>",
"      ]. No oral cleft abnormalities were noted in the glucocorticoid group.",
"     </li>",
"     <li>",
"      Preterm birth and low birth weight &ndash; A large, prospective, cohort study of 2123 pregnant women with asthma recruited from 16 centers in the United States in the period from December 1994 to February 2000 found that oral glucocorticoid use was significantly associated with preterm birth (odds ratio 1.54, 95% CI of 1.02 to 2.33) and low birth weight (odds ratio 1.80, 95% CI of 1.13 to 2.88) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/14\">",
"       14",
"      </a>",
"      ]. Increased prematurity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lower birth weights have been noted in other studies as well [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/31,49,50,52-55\">",
"       31,49,50,52-55",
"      </a>",
"      ]. The authors did not evaluate the relationship between these effects and the dose or duration of therapy.",
"     </li>",
"     <li>",
"      Other adverse outcomes &ndash; Preeclampsia has been attributed to oral glucocorticoid use in several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/30,56,57\">",
"       30,56,57",
"      </a>",
"      ]. Neonatal adrenal insufficiency following maternal administration of glucocorticoids is distinctly unusual, probably because the nonhalogenated glucocorticoids do not readily cross the placenta [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/27\">",
"       27",
"      </a>",
"      ]. Gestational diabetes and hypertension are additional potential maternal complications of systemic glucocorticoid administration [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, it is difficult to exclude an adverse pregnancy effect due to asthma in studies of patients with asthma symptoms severe enough to require oral glucocorticoids. In addition, the potential gestational risks of oral glucocorticoids must be balanced against the risks to the mother or the infant of inadequately treated disease. In the case of asthma, the risks of severe uncontrolled disease (which may include maternal or fetal mortality) are generally considered to be the greater risk, suggesting that oral glucocorticoids should still be used when indicated for the management of severe gestational asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21,34\">",
"     21,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Inhaled",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to",
"    <span class=\"nowrap\">",
"     oral/systemic",
"    </span>",
"    glucocorticoids, the safety data on inhaled glucocorticoids are reassuring [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/14,17,32,49,57-66\">",
"     14,17,32,49,57-66",
"    </a>",
"    ]. The safety of these medicines was best assessed in a registry-based cohort study of 2014 Swedish women who used inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    during early pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/17\">",
"     17",
"    </a>",
"    ]. The rate of congenital malformations was not different from that of the general population (3.8 versus 3.5 percent). Additional data from the Swedish Medical Birth Registry reported no clinically significant effects of inhaled budesonide on fetal mortality, gestational age, or fetal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/39\">",
"     39",
"    </a>",
"    ]. Based largely upon these findings, budesonide is currently the only inhaled glucocorticoid with a pregnancy category B rating [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a separate study of 13,280 pregnancies in women with asthma confirmed that low to moderate doses of inhaled glucocorticoids were NOT associated with an increased risk of congenital malformations. However, the use of high doses (&gt;1000",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    during the first trimester was associated with a 63 percent increase in risk of all congenital malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/63\">",
"     63",
"    </a>",
"    ]. The strength of this observation is limited because the study was underpowered to assess the risk of specific malformations, such as cleft palate, which has been associated with maternal use of systemic glucocorticoids. In addition, the authors could not exclude the possibility that greater asthma severity contributed to the overall increased risk of malformations. Benefit-risk considerations favor the use of high dose inhaled glucocorticoids over a lower dose when needed for asthma control to avoid the use of systemic oral glucocorticoids, with the potential risks listed above. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Oral/Systemic'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Two randomized controlled trials support the efficacy of inhaled glucocorticoids during pregnancy. One study assessed 84 pregnant women who were managed with or without inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"     beclomethasone",
"    </a>",
"    after discharge following an asthma hospitalization during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/67\">",
"     67",
"    </a>",
"    ]. Use of this medication significantly decreased the rate of readmission for asthma (12 versus 33 percent), and no adverse events or outcomes were reported. A more recent study compared inhaled beclomethasone to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in the management of moderate asthma during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/60\">",
"     60",
"    </a>",
"    ]. Although exacerbation rates were similar in the two groups, pulmonary function was better in the beclomethasone group and fewer patients in the beclomethasone group discontinued therapy due to side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Anticholinergic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticholinergic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    , are not generally used as a primary form of therapy for asthma. However, questions may arise about their safety during pregnancy.",
"   </p>",
"   <p>",
"    Fetal tachycardia can occur with the systemic administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    to the mother; however, the minimal chronotropic effect of inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    in the mother suggests that the inhaled preparation should have negligible chronotropic effects on the fetus. Gestational animal studies are also reassuring for ipratropium [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/27\">",
"     27",
"    </a>",
"    ]. Consequently,",
"    <strong>",
"     inhaled ipratropium",
"    </strong>",
"    , the most commonly used drug in this category, is felt to be safe during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21,68\">",
"     21,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Methylxanthines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive clinical experience suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    and its ethylenediamine complex,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    , do not increase the risk of adverse effects during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/13,30,37,69\">",
"     13,30,37,69",
"    </a>",
"    ]. However, the clinical use of these medications is limited because of the potential for altered metabolism during pregnancy and the need for drug level monitoring. Moreover, inhaled glucocorticoids have been shown to be more effective than theophylline for persistent asthma in non-pregnant patients and at least as effective as theophylline with fewer side effects in pregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21,60\">",
"     21,60",
"    </a>",
"    ]. Thus, theophylline could be considered as an add-on therapy to inhaled glucocorticoids for pregnant women if needed [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Alterations in drug metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two changes of potential clinical importance in the bioavailability and metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    during pregnancy. Decreased binding to albumin results in an increased proportion of free drug in the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/70\">",
"     70",
"    </a>",
"    ]. The free drug concentration itself does not change because the decrease in binding means that more free drug is available for metabolism. However, the total (free plus bound) theophylline concentration falls. As a result, target plasma levels during pregnancy are 8 to 12 rather than 10 to 15",
"    <span class=\"nowrap\">",
"     micrograms/mL.",
"    </span>",
"    This can be achieved without change in drug dose due to the relative constancy of the free drug concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=see_link\">",
"     \"Theophylline use in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second change is that the clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    appears to decrease during the third trimester, possibly requiring a reduction in the maintenance dose [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/71\">",
"     71",
"    </a>",
"    ]. With an intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    infusion during the third trimester, for example, the loading dose of 5 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is unchanged, but the maintenance infusion rate is decreased from 0.9",
"    <span class=\"nowrap\">",
"     mg/kg/hr",
"    </span>",
"    to approximately 0.5",
"    <span class=\"nowrap\">",
"     mg/kg/hr;",
"    </span>",
"    the dose is then adjusted to maintain the desired plasma level of 8 to 12",
"    <span class=\"nowrap\">",
"     micrograms/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Like the beta-2 adrenergic agonists,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    can also inhibit uterine muscle contraction in vitro. This effect is presumably mediated by an inhibitory action of increased cyclic AMP (due to theophylline-induced phosphodiesterase inhibition) on uterine smooth muscle, but has not been shown to be clinically important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Effect on the fetus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methylxanthines are transferred across the placenta, leading to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    concentrations in neonatal and cord blood that are similar to those in maternal blood [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/72\">",
"     72",
"    </a>",
"    ]. Transient tachycardia and irritability have been reported in some neonates of mothers receiving methylxanthines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Cromoglycates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal data and limited data in human pregnancies (n = 318) have not demonstrated an increase in fetal malformations or other adverse effects with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/30,68\">",
"     30,68",
"    </a>",
"    ]. The one study that reported an increase in musculoskeletal abnormalities with maternal use of chromones had a very small number of exposures (n = 5), limiting the strength of the observation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/7\">",
"     7",
"    </a>",
"    ]. Human data are not available for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    , although preclinical animal studies suggest that this drug does not increase the risk of adverse effects in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=see_link\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The availability of the cromoglycates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/53/37712?source=see_link\">",
"     cromolyn sodium",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    , is limited and varies from one country to another. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=see_link&amp;anchor=H2#H2\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\", section on 'Limitations on availability'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Leukotriene modifiers",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     Zafirlukast",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    (leukotriene receptor antagonists) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    (a 5&ndash;lipoxygenase inhibitor) are agents that affect leukotriene synthesis or action. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data on the use of these agents in pregnancy are limited, but accumulating evidence, particularly about",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    , is reassuring.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first prospective, controlled study of the use of leukotriene receptor antagonists in pregnancy followed 96 women taking these medications, 122 women taking SABAs only, and 346 women without asthma. No increase in major birth defects or adverse outcomes was detected in the offspring of patients receiving these medications [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/73\">",
"       73",
"      </a>",
"      ]. A subsequent study with similar design described 180",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      -exposed pregnancies compared to 180 disease matched controls and 180 pregnancies in non-asthmatic women. In this study, montelukast did not appear to increase the baseline rate of major malformations, although lower birth weights were seen in both asthmatic groups [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/74\">",
"       74",
"      </a>",
"      ]. Larger studies are needed to detect small increases in adverse pregnancy outcomes or rare birth defects.",
"      <br/>",
"      <br/>",
"      Data from the Merck Pregnancy Registry that have not been published describe 401 prospective reports of mothers exposed to montelukast during pregnancy, in which 203 reports were complete and reported pregnancy outcomes. There were 250 live births (three sets of twins), four miscarriages, and two elective abortions. Congenital limb defects have rarely been reported in children whose mothers were exposed to montelukast during pregnancy, but a causal association has not been established. The overall rates of congenital malformations, preterm births, and small-for-dates infants in the Merck prospective registry were 2.8, 11, and 5 percent, respectively. These results are consistent with those expected in the general population.",
"      <br/>",
"      <br/>",
"      No teratogenicity was observed with montelukast given to rats or rabbits at doses greater than 300 times the maximum human daily oral dose on an",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      basis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Animal data on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      have shown no teratogenicity at oral doses up to 160 times the maximum human daily oral dose on a",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      basis [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are currently no adequate and well&ndash;controlled studies of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"       zileuton",
"      </a>",
"      in pregnant women, and animal studies have not been reassuring [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, until further information is available, we suggest use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    in preference to the other leukotriene modifiers, and would reserve this agent for add-on therapy to inhaled glucocorticoids, especially in patients who had a good response to this medication prior to pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3498674\">",
"    <span class=\"h2\">",
"     Immunotherapy for allergic asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initiation of allergen immunotherapy is not recommended during pregnancy based upon risk-benefit considerations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/29\">",
"     29",
"    </a>",
"    ]. However, aside from the risk of systemic reactions, allergy immunotherapy appears to confer minimal additional risk during pregnancy. Thus, allergen",
"    <strong>",
"     immunotherapy can be continued",
"    </strong>",
"    during pregnancy in patients already receiving it who appear to be deriving benefit, who are not prone to systemic reactions, and who are receiving a maintenance concentration or at least a substantial dosage. Immunotherapy during pregnancy is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=see_link&amp;anchor=H17#H17\">",
"     \"Recognition and management of allergic disease during pregnancy\", section on 'Allergen immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     OVERVIEW OF ASTHMA MANAGEMENT IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles of pharmacologic therapy for asthma during pregnancy are similar to those in nonpregnant patients and involve a step-wise approach, as recommended by the \"The National Asthma Education and Prevention Program: Expert Panel Report 3&rdquo; (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53233 \" href=\"UTD.htm?38/33/39453\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/78\">",
"     78",
"    </a>",
"    ]. The details of this approach are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Working Group on Asthma and Pregnancy of the National Asthma Education Program reviewed the available data on asthma medications and made recommendations regarding medication preferences in the management of chronic asthma, acute asthma, respiratory infections, and peripartum care during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/21,78,79\">",
"     21,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Chronic asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NAEPP 2007 recommendations for the management of chronic asthma during pregnancy are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef55513 \" href=\"UTD.htm?10/11/10428\">",
"     table 6",
"    </a>",
"    ). The following points are emphasized:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Either medium dose inhaled glucocorticoids or combination low dose inhaled glucocorticoids plus a long acting beta agonist (LABA) are recommended for the initial management of moderate persistent asthma; our preference is for the former due to the greater experience with inhaled glucocorticoids than with LABAs during pregnancy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       Albuterol",
"      </a>",
"      is recommended as the short-acting beta agonist of choice.",
"     </li>",
"     <li>",
"      Because there are more published gestational human data for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/17,80\">",
"       17,80",
"      </a>",
"      ], it is the preferred inhaled glucocorticoid for use during pregnancy. However, other inhaled glucocorticoids could be continued if the patient was well-controlled on one of these medications prior to pregnancy.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       Salmeterol",
"      </a>",
"      is recommended as the inhaled long-acting beta agonist of choice in the United States due to the longer duration of clinical experience with this agent compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       Montelukast",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      could be considered as alternative but NOT preferred therapy for mild persistent asthma or as add-on therapy to inhaled glucocorticoids, especially for patients who have shown a uniquely favorable response prior to pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Acute exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended pharmacotherapy of acute asthma during pregnancy does not differ substantially from the management in non-pregnant patients (",
"    <a class=\"graphic graphic_table graphicRef67529 \" href=\"UTD.htm?35/32/36364\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/81\">",
"     81",
"    </a>",
"    ]. Intensive monitoring of both mother and fetus is essential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"     \"Overview of fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272296412\">",
"    <span class=\"h3\">",
"     Supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen (initially 3 to 4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    by nasal cannula) should be administered, adjusting the fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ) to maintain an arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) of at least 70 mmHg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oxygen saturation by pulse oximetry of 95 percent or greater [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/82\">",
"     82",
"    </a>",
"    ]. Intravenous fluids (containing glucose if the patient is not hyperglycemic) are administered, if needed to ensure adequate hydration. Pregnant patients with acute asthma should rest in a seated, rather than supine, position.",
"   </p>",
"   <p>",
"    Continuous fetal heart rate monitoring as well as maternal monitoring is essential, and the fetal heart rate tracing should be evaluated by a clinician experienced in fetal heart rate assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Interpretation of arterial blood gases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The changes in blood gases that occur secondary to acute asthma during pregnancy are superimposed on the \"normal\" respiratory alkalosis of pregnancy. Thus, an arterial carbon dioxide tension (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) &gt;35 mmHg or an arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) &lt;70 mmHg associated with acute asthma represent more severe compromise during pregnancy than in the non-gravid state. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=see_link\">",
"     \"Physiology and clinical course of asthma in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommended agents for management of acute asthma exacerbations in pregnant patients include inhaled beta agonists, inhaled anticholinergic agents, oral or intravenous glucocorticoids, and, if appropriate, intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef67529 \" href=\"UTD.htm?35/32/36364\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .) Additional points regarding pharmacotherapy include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dosages of systemic glucocorticoids for acute asthma exacerbations in pregnancy are not different than those recommended for non-pregnant patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/83\">",
"       83",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of acute exacerbations of asthma in adults\", section on 'Systemic glucocorticoids'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"        aminophylline",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"        theophylline",
"       </a>",
"      </span>",
"      is NOT generally recommended for use in the emergency management of acute gestational asthma because it has been demonstrated that",
"      <span class=\"nowrap\">",
"       aminophylline/theophylline",
"      </span>",
"      provides no additional benefit to optimal inhaled beta agonist and intravenous glucocorticoid therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/67,82\">",
"       67,82",
"      </a>",
"      ]. In addition, when used in combination with intensive inhaled beta-agonist therapy, intravenous aminophylline causes increased adverse side effects [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      may be beneficial in acute severe asthma as an adjunct to inhaled beta agonists and intravenous glucocorticoids, especially in patients with coexistent hypertension or preterm uterine contractions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/83\">",
"       83",
"      </a>",
"      ]. Magnesium sulfate is among the most extensively studied medications in pregnancy. It is routinely given to prevent eclamptic seizures in the mother and appears to have neuroprotective effects for the neonate if administered prior to preterm birth. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link&amp;anchor=H20#H20\">",
"       \"Treatment of acute exacerbations of asthma in adults\", section on 'Magnesium sulfate'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43799?source=see_link\">",
"       \"Neuroprotective effects of in utero exposure to magnesium sulfate\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed discussion of the treatment of acute exacerbations of asthma, including status asthmaticus, is provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=see_link\">",
"     \"Treatment of acute exacerbations of asthma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Respiratory infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most respiratory infections that trigger an exacerbation of asthma are viral rather than bacterial and do not require antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/78\">",
"     78",
"    </a>",
"    ]. The treatment of respiratory infections during pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36344?source=see_link\">",
"     \"Treatment of respiratory infections in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Peripartum care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few additional issues are relevant to the peripartum management of the asthmatic patient [",
"    <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/82\">",
"     82",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       Oxytocin",
"      </a>",
"      is the drug of choice for induction of labor and control of postpartum hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/84\">",
"       84",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link&amp;anchor=H6#H6\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\", section on 'Uterotonic drugs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27336?source=see_link&amp;anchor=H4#H4\">",
"       \"Management of postpartum hemorrhage at cesarean delivery\", section on 'Initial management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link&amp;anchor=H10700778#H10700778\">",
"       \"Principles of labor induction\", section on 'Guidelines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Analogs of prostaglandin F2&ndash;alpha can cause bronchoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/85,86\">",
"       85,86",
"      </a>",
"      ] and should not be used for termination of pregnancy, cervical ripening, induction of labor, or control of uterine hemorrhage. Prostaglandin E2 (in gel or suppository form) and prostaglandin E1 (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/41/662?source=see_link\">",
"       misoprostol",
"      </a>",
"      ) have not been reported to cause bronchoconstriction and are safer analogs if prostaglandin treatment is required [",
"      <a class=\"abstract\" href=\"UTD.htm?28/34/29226/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For peripartum pain control,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      should be avoided, if possible, since they can induce histamine release, however, evidence of acute bronchoconstriction caused by these agents is lacking.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"       Butorphanol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       fentanyl",
"      </a>",
"      may be appropriate alternatives.",
"     </li>",
"     <li>",
"      Epidural anesthesia is preferred for the asthmatic patient who opts for pain control during labor because it reduces oxygen consumption and minute ventilation in the first and second stage of labor and usually can provide adequate anesthesia if cesarean delivery becomes necessary.",
"     </li>",
"     <li>",
"      If general anesthesia is required,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"       ketamine",
"      </a>",
"      and halogenated anesthetics are preferred, because they may have a bronchodilatory effect.",
"     </li>",
"     <li>",
"      Use of ergot derivatives for postpartum bleeding or headache should be avoided because of their potential to cause bronchoconstriction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/21/18770?source=see_link\">",
"       \"Patient information: Asthma and pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=see_link\">",
"       \"Patient information: Asthma and pregnancy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H102656489\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asthma may improve, worsen, or remain unchanged in severity during pregnancy. The potential mechanisms involved and clinical implications of these findings are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=see_link\">",
"       \"Physiology and clinical course of asthma in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The two primary goals of asthma therapy during pregnancy are the prevention of acute exacerbations and optimization of ongoing pulmonary function. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'General care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The four important components of effective asthma therapy during pregnancy are (see",
"      <a class=\"local\" href=\"#H6\">",
"       'General care'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Objective monitoring of maternal lung function and fetal well&ndash;being as a guide to therapy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H6#H6\">",
"       \"An overview of asthma management\", section on 'Monitoring patients with asthma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"       \"Overview of fetal assessment\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Proper control of environmental and other triggers for asthma (eg, cigarette smoking, animal allergen exposure) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"       \"Trigger control to enhance asthma management\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Patient education (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"       \"What do patients need to know about their asthma?\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Pharmacologic therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies are reassuring regarding a lack of adverse effects on human pregnancy outcomes with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"       metaproterenol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/7/33904?source=see_link\">",
"       beclomethasone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      . Reassuring animal studies have been reported with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"       nedocromil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"       zafirlukast",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      , but published experience in human pregnancy with these agents is limited. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The general principles of pharmacologic therapy for asthma during pregnancy are similar to those in nonpregnant patients and involve a step-wise approach, as recommended by the \"The National Asthma Education and Prevention Program (NAEPP): Expert Panel Report 3&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53233 \" href=\"UTD.htm?38/33/39453\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef55513 \" href=\"UTD.htm?10/11/10428\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Overview of asthma management in pregnancy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"       \"An overview of asthma management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A few medication preferences have been identified for asthma management during pregnancy based on greater experience in treating patients with these medications (see",
"      <a class=\"local\" href=\"#H27\">",
"       'Chronic asthma'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For relief of acute asthma symptoms, we suggest using the short-acting beta agonist (SABA)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      , rather than other SABAs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For patients who require a long-term controller for asthma, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      as the preferred inhaled glucocorticoid (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, other inhaled glucocorticoids can be continued if the patient was well-controlled on one of these medications prior to pregnancy or if a higher dose of inhaled glucocorticoid is needed than is available with budesonide.",
"     </li>",
"     <li>",
"      For the initial management of moderate persistent asthma, national guidelines suggest either medium dose inhaled glucocorticoids or the combination of low dose inhaled glucocorticoids plus a long acting beta agonist (LABA); we suggest using medium dose inhaled glucocorticoids due to the greater experience with inhaled glucocorticoids than with LABAs during pregnancy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Chronic asthma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of moderate persistent asthma in adolescents and adults\", section on 'Preferred options'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of acute asthma exacerbations during pregnancy does not differ substantially from that of non-pregnant patients and includes inhaled short-acting beta agonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      , inhaled anticholinergic agents, oral or intravenous glucocorticoids, and, if appropriate, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      (",
"      <a class=\"graphic graphic_table graphicRef67529 \" href=\"UTD.htm?35/32/36364\">",
"       table 3",
"      </a>",
"      ). Intensive monitoring of both mother and fetus is essential. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Acute exacerbations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential areas of concern have been raised with the use of systemic glucocorticoids, including slightly increased risks of congenital malformations (primarily cleft palate), preeclampsia, low birth weight, and neonatal adrenal insufficiency. However, these potential risks of systemic glucocorticoids are small compared with the substantial risk to the mother and fetus of severe, uncontrolled asthma. Dosages of glucocorticoids for treatment of acute asthma exacerbations in pregnancy are not different than those for non-pregnant patients. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Oral/Systemic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the rare patient who requires use of a systemic beta-agonist to treat asthma, we suggest subcutaneous administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      rather than epinephrine (",
"      <a class=\"graphic graphic_table graphicRef67529 \" href=\"UTD.htm?35/32/36364\">",
"       table 3",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is based on a concern about potential uterine artery vasoconstriction with systemic administration of epinephrine (",
"      <a class=\"graphic graphic_table graphicRef67529 \" href=\"UTD.htm?35/32/36364\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Epinephrine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not initiating allergen immunotherapy during pregnancy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, allergen immunotherapy can be continued during pregnancy in patients already receiving it who appear to be deriving benefit, who are not prone to systemic reactions, and who are receiving a maintenance concentration or at least a substantial dosage. (See",
"      <a class=\"local\" href=\"#H3498674\">",
"       'Immunotherapy for allergic asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pharmacologic induction of labor and control of postpartum hemorrhage in patients with asthma,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      appears to be safe in pregnancy. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Peripartum care'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link&amp;anchor=H6#H6\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\", section on 'Uterotonic drugs'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link&amp;anchor=H7537379#H7537379\">",
"       \"Principles of labor induction\", section on 'Oxytocin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with asthma who require prostaglandin treatment for termination of pregnancy, cervical ripening, induction of labor, or control of uterine hemorrhage, we recommend using prostaglandin E1 or E2, rather than analogs of prostaglandin F2&ndash;alpha (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). This recommendation is based on the risk of bronchoconstriction associated with the latter agent. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Peripartum care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/1\">",
"      Namazy JA, Schatz M. Pregnancy and asthma: recent developments. Curr Opin Pulm Med 2005; 11:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/2\">",
"      Liccardi G, Cazzola M, Canonica GW, et al. General strategy for the management of bronchial asthma in pregnancy. Respir Med 2003; 97:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/3\">",
"      Tan KS, Thomson NC. Asthma in pregnancy. Am J Med 2000; 109:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/4\">",
"      Dombrowski MP, Schatz M, Wise R, et al. Asthma during pregnancy. Obstet Gynecol 2004; 103:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/5\">",
"      Kwon HL, Belanger K, Bracken MB. Asthma prevalence among pregnant and childbearing-aged women in the United States: estimates from national health surveys. Ann Epidemiol 2003; 13:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/6\">",
"      Schatz, M, Dombrowski, M. Outcomes of pregnancy in asthmatic women. Immunol Allergy Clin North Am 2000; 20:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/7\">",
"      Tata LJ, Lewis SA, McKeever TM, et al. Effect of maternal asthma, exacerbations and asthma medication use on congenital malformations in offspring: a UK population-based study. Thorax 2008; 63:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/8\">",
"      Schatz M, Zeiger RS, Harden K, et al. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 1997; 100:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/9\">",
"      Correa A, Cragan JD, Kucik JE, et al. Reporting birth defects surveillance data 1968-2003. Birth Defects Res A Clin Mol Teratol 2007; 79:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/10\">",
"      K&auml;ll&eacute;n B, Rydhstroem H, Aberg A. Asthma during pregnancy--a population based study. Eur J Epidemiol 2000; 16:167.",
"     </a>",
"    </li>",
"    <li>",
"     Scialli A, Lone A. Pregnancy effects of specific medications used to treat asthma and immunological diseases. In: Asthma and immunological diseases in pregnancy and early infancy, Schatz M, Zeiger RS, Claman HN (Eds), Marcel Dekker, New York 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/12\">",
"      Petitti, DB. Perinatal epidemiology: Studying the effects of illness and medications during pregnancy. Immunol Allergy Clin North Am 2000; 20:673.",
"     </a>",
"    </li>",
"    <li>",
"     Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy, PSG Publishing, Littleton, MA 1977.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/14\">",
"      Schatz M, Dombrowski MP, Wise R, et al. The relationship of asthma medication use to perinatal outcomes. J Allergy Clin Immunol 2004; 113:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/15\">",
"      Specific requirements on content and format of labeling for human prescription drugs. Fed Reg 1979; 44:37462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/16\">",
"      Scialli AR, Buelke-Sam JL, Chambers CD, et al. Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity studies in pregnancy labels for drugs. Birth Defects Res A Clin Mol Teratol 2004; 70:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/17\">",
"      K&auml;ll&eacute;n B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999; 93:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/18\">",
"      Polifka, JE, Jones, KL. General considerations regarding the use of asthma and allergy medications during pregnancy. Immunol Allergy Clin North Am 2000; 20:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/19\">",
"      Kweder SL. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century. Birth Defects Res A Clin Mol Teratol 2008; 82:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/20\">",
"      Namazy JA, Schatz M. Update in the treatment of asthma during pregnancy. Clin Rev Allergy Immunol 2004; 26:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/21\">",
"      National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program Asthma and Pregnancy Working Group. NAEPP expert panel report. Managing asthma during pregnancy: recommendations for pharmacologic treatment-2004 update. J Allergy Clin Immunol 2005; 115:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/22\">",
"      Schatz M, Dombrowski MP, Wise R, et al. Spirometry is related to perinatal outcomes in pregnant women with asthma. Am J Obstet Gynecol 2006; 194:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/23\">",
"      Schatz M, Zeiger RS, Hoffman CP. Intrauterine growth is related to gestational pulmonary function in pregnant asthmatic women. Kaiser-Permanente Asthma and Pregnancy Study Group. Chest 1990; 98:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/24\">",
"      Newman RB, Momirova V, Dombrowski MP, et al. The effect of active and passive household cigarette smoke exposure on pregnant women with asthma. Chest 2010; 137:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/25\">",
"      Murphy VE, Clifton VL, Gibson PG. The effect of cigarette smoking on asthma control during exacerbations in pregnant women. Thorax 2010; 65:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/26\">",
"      Blais L, Forget A. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. J Allergy Clin Immunol 2008; 121:1379.",
"     </a>",
"    </li>",
"    <li>",
"     Schatz, M, Hoffman, CP, Zeiger, RS, et al. Asthma and allergic diseases during pregnancy. In: Middleton's Allergy: Principles and Practice, 6th, Adkinson, NF, Yunginger, JW, Busse, WW, et al (Eds), Mosby, St. Louis, MO 2003. p.1303.",
"    </li>",
"    <li>",
"     Brown, WA. Psychological care during pregnancy and the postpartum period, Raven Press, New York 1979.",
"    </li>",
"    <li>",
"     Breathing for Two. A Guide to Asthma During Pregnancy. Asthma &amp; Allergy Network Mothers of Asthmatics (AANMA), 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/30\">",
"      Schatz M. The efficacy and safety of asthma medications during pregnancy. Semin Perinatol 2001; 25:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/31\">",
"      Bracken MB, Triche EW, Belanger K, et al. Asthma symptoms, severity, and drug therapy: a prospective study of effects on 2205 pregnancies. Obstet Gynecol 2003; 102:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/32\">",
"      Namazy J, Schatz M, Long L, et al. Use of inhaled steroids by pregnant asthmatic women does not reduce intrauterine growth. J Allergy Clin Immunol 2004; 113:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/33\">",
"      Schatz M. Asthma and pregnancy. Lancet 1999; 353:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/34\">",
"      Dombrowski MP, Schatz M, ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 90, February 2008: asthma in pregnancy. Obstet Gynecol 2008; 111:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/35\">",
"      Vasilakis-Scaramozza C, Aschengrau A, Cabral HJ, Jick SS. Asthma drugs and the risk of congenital anomalies. Pharmacotherapy 2013; 33:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/36\">",
"      Schatz M, Zeiger RS, Harden KM, et al. The safety of inhaled beta-agonist bronchodilators during pregnancy. J Allergy Clin Immunol 1988; 82:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/37\">",
"      Stenius-Aarniala B, Riikonen S, Teramo K. Slow-release theophylline in pregnant asthmatics. Chest 1995; 107:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/38\">",
"      Wilson, I. Utilisation du cromoglycate de sodium au cours de la grossesse. Acta Therapeutica 1982; 8:45S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/39\">",
"      Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2,968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003; 111:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/40\">",
"      Lin S, Munsie JP, Herdt-Losavio ML, et al. Maternal asthma medication use and the risk of gastroschisis. Am J Epidemiol 2008; 168:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/41\">",
"      K&auml;ll&eacute;n B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy. 3. Congenital malformations in the infants. Eur J Clin Pharmacol 2007; 63:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/42\">",
"      Martel MJ, Rey E, Beauchesne MF, et al. Use of short-acting beta2-agonists during pregnancy and the risk of pregnancy-induced hypertension. J Allergy Clin Immunol 2007; 119:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/43\">",
"      Bennett JA, Smyth ET, Pavord ID, et al. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; 49:771.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.reprotox.org/Members/AgentDetail.aspx?a=3721 (Accessed on May 06, 2011).",
"    </li>",
"    <li>",
"     file://www.reprotox.org/Members/AgentDetail.aspx?a=4360 (Accessed on May 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/46\">",
"      Wilton LV, Shakir SA. A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England. Drug Saf 2002; 25:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/47\">",
"      The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). Ann Allergy Asthma Immunol 2000; 84:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/48\">",
"      Schatz M, Dombrowski MP. Clinical practice. Asthma in pregnancy. N Engl J Med 2009; 360:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/49\">",
"      Bakhireva LN, Jones KL, Schatz M, et al. Asthma medication use in pregnancy and fetal growth. J Allergy Clin Immunol 2005; 116:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/50\">",
"      Fitzsimons R, Greenberger PA, Patterson R. Outcome of pregnancy in women requiring corticosteroids for severe asthma. J Allergy Clin Immunol 1986; 78:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/51\">",
"      Schatz M, Patterson R, Zeitz S, et al. Corticosteroid therapy for the pregnant asthmatic patient. JAMA 1975; 233:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/52\">",
"      Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/53\">",
"      Gur C, Diav-Citrin O, Shechtman S, et al. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/54\">",
"      Perlow JH, Montgomery D, Morgan MA, et al. Severity of asthma and perinatal outcome. Am J Obstet Gynecol 1992; 167:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/55\">",
"      Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. Science 1978; 202:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/56\">",
"      Stenius-Aarniala B, Piiril&auml; P, Teramo K. Asthma and pregnancy: a prospective study of 198 pregnancies. Thorax 1988; 43:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/57\">",
"      Martel MJ, Rey E, Beauchesne MF, et al. Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study. BMJ 2005; 330:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/58\">",
"      Greenberger PA, Patterson R. Beclomethasone diproprionate for severe asthma during pregnancy. Ann Intern Med 1983; 98:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/59\">",
"      Dombrowski MP, Brown CL, Berry SM. Preliminary experience with triamcinolone acetonide during pregnancy. J Matern Fetal Med 1996; 5:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/60\">",
"      Dombrowski MP, Schatz M, Wise R, et al. Randomized trial of inhaled beclomethasone dipropionate versus theophylline for moderate asthma during pregnancy. Am J Obstet Gynecol 2004; 190:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/61\">",
"      Dombrowski M, Thom E, McNellis D. Maternal-Fetal Medicine Units (MFMU) studies of inhaled corticosteroids during pregnancy. J Allergy Clin Immunol 1999; 103:S356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/62\">",
"      Blais L, Beauchesne MF, Rey E, et al. Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma. Thorax 2007; 62:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/63\">",
"      Blais L, Beauchesne MF, Lemi&egrave;re C, Elftouh N. High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations. J Allergy Clin Immunol 2009; 124:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/64\">",
"      Breton MC, Beauchesne MF, Lemi&egrave;re C, et al. Risk of perinatal mortality associated with inhaled corticosteroid use for the treatment of asthma during pregnancy. J Allergy Clin Immunol 2010; 126:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/65\">",
"      Hodyl NA, Stark MJ, Osei-Kumah A, et al. Fetal glucocorticoid-regulated pathways are not affected by inhaled corticosteroid use for asthma during pregnancy. Am J Respir Crit Care Med 2011; 183:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/66\">",
"      Tegethoff M, Greene N, Olsen J, et al. Inhaled glucocorticoids during pregnancy and offspring pediatric diseases: a national cohort study. Am J Respir Crit Care Med 2012; 185:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/67\">",
"      Wendel PJ, Ramin SM, Barnett-Hamm C, et al. Asthma treatment in pregnancy: a randomized controlled study. Am J Obstet Gynecol 1996; 175:150.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program Expert Panel Executive Summary Report: Guidelines for the Diagnosis and Management of Asthma - Update on Selected Topics 2002. National Institutes of Health, National Heart, Lung, and Blood Institute, Publication No. 02-5075, 2002. www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf (Accessed on March 1, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/69\">",
"      Neff RK, Leviton A. Maternal theophylline consumption and the risk of stillbirth. Chest 1990; 97:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/70\">",
"      Connelly TJ, Ruo TI, Frederiksen MC, Atkinson AJ Jr. Characterization of theophylline binding to serum proteins in pregnant and nonpregnant women. Clin Pharmacol Ther 1990; 47:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/71\">",
"      Carter BL, Driscoll CE, Smith GD. Theophylline clearance during pregnancy. Obstet Gynecol 1986; 68:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/72\">",
"      Labovitz E, Spector S. Placental theophylline transfer in pregnant asthmatics. JAMA 1982; 247:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/73\">",
"      Bakhireva LN, Jones KL, Schatz M, et al. Safety of leukotriene receptor antagonists in pregnancy. J Allergy Clin Immunol 2007; 119:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/74\">",
"      Sarkar M, Koren G, Kalra S, et al. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. Eur J Clin Pharmacol 2009; 65:1259.",
"     </a>",
"    </li>",
"    <li>",
"     Reprotox. file://www.reprotox.org/Members/AgentDetail.aspx?a=4087 (Accessed on May 06, 2011).",
"    </li>",
"    <li>",
"     Reprotox. file://www.reprotox.org/Members/AgentDetail.aspx?a=3993 (Accessed on May 06, 2011).",
"    </li>",
"    <li>",
"     Reprotox. file://www.reprotox.org/Members/AgentDetail.aspx?a=3722.",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     Quick Reference. NAEPP Expert Panel Report Managing Asthma During Pregnancy: Recommendations for Phamacologic Treatment&mdash;Update 2004 NIH Publication No. 04-5246. US Dept of Health and human Services, Bethesda, MD, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/80\">",
"      Ericson, A, Kallen, B. Use of drugs during pregnancy&mdash;unique Swedish registration method can be improved. Information from the Swedish Medical Products Agency 1999; 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/81\">",
"      Cydulka RK. Acute asthma during pregnancy. Immunol Allergy Clin North Am 2006; 26:103.",
"     </a>",
"    </li>",
"    <li>",
"     Management of asthma during pregnancy: Report of the Working Group on Asthma and Pregnancy NIH Publication No. 93-3279. National Asthma Education Program; National Institutes of Health, Bethesda, MD, 1993.",
"    </li>",
"    <li>",
"     Schatz, M, Wise, RA. Acute asthma in pregnancy. In: Acute Asthma: Assessment and Management, Corbridge T, et al (Eds), McGraw-Hill, New York 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/84\">",
"      Minerbi-Codish I, Fraser D, Avnun L, et al. Influence of asthma in pregnancy on labor and the newborn. Respiration 1998; 65:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/85\">",
"      Arakawa H, L&ouml;tvall J, Kawikova I, et al. Leukotriene D4- and prostaglandin F2 alpha-induced airflow obstruction and airway plasma exudation in guinea-pig: role of thromboxane and its receptor. Br J Pharmacol 1993; 110:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/86\">",
"      Kawikova I, Barnes PJ, Takahashi T, et al. 8-Epi-PGF2 alpha, a novel noncyclooxygenase-derived prostaglandin, constricts airways in vitro. Am J Respir Crit Care Med 1996; 153:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/34/29226/abstract/87\">",
"      Towers CV, Briggs GG, Rojas JA. The use of prostaglandin E2 in pregnant patients with asthma. Am J Obstet Gynecol 2004; 190:1777.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 554 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29226=[""].join("\n");
var outline_f28_34_29226=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H102656489\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF MEDICATIONS IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Potential adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Assessing risk of medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Altered pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENERAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Monitoring lung function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Environmental control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SAFETY OF SPECIFIC MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H369937555\">",
"      Inhaled beta-adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Short-acting beta-adrenergic agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H369937512\">",
"      - Long-acting beta-adrenergic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Epinephrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Oral/Systemic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Inhaled",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Anticholinergic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Methylxanthines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Alterations in drug metabolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Effect on the fetus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Cromoglycates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Leukotriene modifiers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3498674\">",
"      Immunotherapy for allergic asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      OVERVIEW OF ASTHMA MANAGEMENT IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Chronic asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Acute exacerbations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272296412\">",
"      - Supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Interpretation of arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Respiratory infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Peripartum care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H102656489\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/554\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/554|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/33/44563\" title=\"figure 1\">",
"      Stepwise asthma Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/554|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/27/19899\" title=\"table 1\">",
"      Eur study preg result asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/32/36364\" title=\"table 3\">",
"      Medications for acute asthma in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 4\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/33/39453\" title=\"table 5\">",
"      Adjusting Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/11/10428\" title=\"table 6\">",
"      ACAAI ACOG chronic asthma preg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39446?source=related_link\">",
"      Dyspnea during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/44/27336?source=related_link\">",
"      Management of postpartum hemorrhage at cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43799?source=related_link\">",
"      Neuroprotective effects of in utero exposure to magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/20/14660?source=related_link\">",
"      Patient information: Asthma and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/21/18770?source=related_link\">",
"      Patient information: Asthma and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19159?source=related_link\">",
"      Physiology and clinical course of asthma in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/7/19574?source=related_link\">",
"      Principles of teratology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3914?source=related_link\">",
"      Recognition and management of allergic disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/37/32340?source=related_link\">",
"      Respiratory tract changes during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/53/27482?source=related_link\">",
"      Smoking and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=related_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/56/5002?source=related_link\">",
"      Treatment of acute exacerbations of asthma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36344?source=related_link\">",
"      Treatment of respiratory infections in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_34_29227="NCI CTCAE acneiform rash";
var content_f28_34_29227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F67786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F67786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NCI Common Terminology Criteria for Adverse Events grading schema for treatment-related acneiform rash",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Symptoms and signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Papules and/or pustules covering &lt;10 percent BSA, which may or may not be associated with symptoms of pruritus or tenderness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Papules and/or pustules covering 10 to 30 percent of the BSA, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental ADL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Papules and/or pustules covering &gt;30 percent of the BSA, which may or may not be associated with symptoms of pruritus or tenderness; limiting self-care ADL; associated with local superinfection with oral antibiotics indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        Papules and/or pustules covering any percent of the BSA, which may or may not be associated with symptoms of pruritus or tenderness, and are associated with extensive superinfection with IV antibiotics indicated; life-threatening consequences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADL: activities of daily living; BSA: body surface area; NCI: National Cancer Institute.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.0, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29227=[""].join("\n");
var outline_f28_34_29227=null;
var title_f28_34_29228="Contact lens solutions";
var content_f28_34_29228=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contact lens solutions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Multi-purpose solutions for rinsing, storage and disinfection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Opti-Free Express (Alcon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Opti-Free Replenish (Alcon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Complete (AMO)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Aquify (CibaVision)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Renu (Bausch &amp; Lomb)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Sauflon (Sauflon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; RevitaLens (Abott Medical Optics)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; OptiFree Pure Moist (Alcon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; BioTrue (Bausch and Lomb)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Peroxide systems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         AOSept",
"        </strong>",
"        (CIBA Vision) - Three bottle system: Miraflow (concentrated cleaner), SoftWear saline (to rinse off the Miraflow) and AOSept (neutralized by a catalytic disc in the storage case).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Clear Care",
"        </strong>",
"        (CIBA Vision) - Similar to AOSept but a one-step system with cleaner incorporated into the ClearCare solution and neutralized with a catalytic disc in the storage case.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         UltraCare",
"        </strong>",
"        (Advanced Medical Optics) - Four parts: cleaner, saline rinse, peroxide solution and a neutralizing tablet (solution changes color to indicate neutralization).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Sauflon One-Step",
"        </strong>",
"        (Sauflon USA) - One-step system with added wetting agent. Neutralization is with a catalytic disc. Available only through eye care professionals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Solutions/systems for RGP Lenses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Boston Solutions",
"        </strong>",
"        (Bausch &amp; Lomb) - available retail in three forms: Original, Advance and Simplus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         OptiFree GP",
"        </strong>",
"        (Alcon) - available online and limited retail",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Optimum",
"        </strong>",
"        (Lobob) - available retail, online and through RGP distributors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Menicare",
"        </strong>",
"        (Menicon) - available online and through RGP distributors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RGP: rigid gas permeable.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29228=[""].join("\n");
var outline_f28_34_29228=null;
var title_f28_34_29229="Cowden syndrome testing and clinical criteria of the NCCN";
var content_f28_34_29229=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cowden syndrome clinical criteria and testing guidelines from the National Comprehensive Cancer Network (NCCN)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Testing criteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Individual from a family with a known PTEN mutation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Individual with a personal history of:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - Bannayan-Riley-Ruvalcaba syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            OR",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - Adult Lhermitte-Duclos disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            OR",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - Autism spectrum disorder AND macrocephaly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            OR",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - Two or more biopsy-proven trichilemmomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            OR",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - Two or more major criteria (one macrocephaly)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            OR",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - Three major criteria without macrocephaly",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            OR",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - One major and three or more minor criteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            OR",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - Four or more minor criteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            At-risk individual:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - With a relative who has a clinical diagnosis of Cowden syndrome or Bannayan-Riley-Ruvalcaba syndrome for whom testing has not been performed",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            AND",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            - Who has any one major criterion or two minor criteria",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Clinical criteria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Major",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Breast cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2_start\">",
"            Mucocutaneous lesions",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            - One biopsy-proven trichilemmoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            - Multiple palmoplantar keratoses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            - Multifocal or extensive oral mucosal papillomatosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            - Multiple cutaneous facial papules (often verrucous)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist2\">",
"            - Macular pigmentation of glans penis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Macroencephaly (megalocephaly, ie, &ge;97th percentile)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Endometrial cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Non-medullary thyroid cancer",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Multiple GI tract hamartomas or ganglioneuromas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Minor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Other thyroid lesions (adenoma, nodule, goiter)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mental retardation (IQ &le;75)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Autism spectrum disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Single GI tract hamartoma or ganglioneuroma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fibrocystic disease of the breast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lipomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Fibromas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Renal cell carcinoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Uterine fibroids",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Tan MH, Mester J, Peterson C, et al. A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet 2011; 88:42 and NCCN Guidelines, Version 1.2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29229=[""].join("\n");
var outline_f28_34_29229=null;
var title_f28_34_29230="Spectrum of frailty";
var content_f28_34_29230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59326&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Potential interventions along the spectrum of frailty in older adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACE unit: Acute Care for Elders unit; GEM: Geriatric Evaluation and Management; PACE: Program for All-Inclusive Care of the Elderly.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Walston JD, Fried LP. Frailty and its Implications for Care. Chapter 9. In: Geriatric Palliative Care, Morrison RS, Meire DE. Oxford University Press, New York 2003. p.93. Copyright &copy;2003 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_34_29230=[""].join("\n");
var outline_f28_34_29230=null;
var title_f28_34_29231="Contents: Neuromuscular disease";
var content_f28_34_29231=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?3/39/3710\">",
"       Rheumatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Neuromuscular disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Neuromuscular disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Acquired noninflammatory muscle disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/33/10777\">",
"           Causes of rhabdomyolysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/55/32632\">",
"           Clinical manifestations and diagnosis of rhabdomyolysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/31/1526\">",
"           Diabetic muscle infarction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6856\">",
"           Drug-induced myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/40/23173\">",
"           Glucocorticoid-induced myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29093\">",
"           Hypothyroid myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/9/2201\">",
"           Major causes of musculoskeletal chest pain",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4695\">",
"           Muscle disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/53/22358\">",
"           Musculoskeletal complications in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/12/23753\">",
"           Musculoskeletal manifestations of systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/51/14137\">",
"           Myopathies of systemic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/60/43976\">",
"           Neuromuscular weakness related to critical illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4711\">",
"           Nocturnal leg cramps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/20/35142\">",
"           Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/41/665\">",
"           Stiff-person syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Channnelopathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/54/871\">",
"           Hyperkalemic periodic paralysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/62/9193\">",
"           Hypokalemic periodic paralysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/38/22119\">",
"           Thyrotoxic periodic paralysis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Clinical evaluation of neuromuscular disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/4/26694\">",
"           Approach to the patient with muscle weakness",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnostic methods",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/13/27863\">",
"           Clinical neurophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/33/30232\">",
"           Diagnostic ultrasound in neuromuscular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/40/13962\">",
"           Electrodiagnostic evaluation of the neuromuscular junction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/29/13785\">",
"           Motor unit number estimation (MUNE)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/56/36745\">",
"           Muscle enzymes in the evaluation of neuromuscular diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/24/29060\">",
"           Muscle examination in the evaluation of weakness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/21/39251\">",
"           Nerve conduction studies: Late responses",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/46/1769\">",
"           Overview of electromyography",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/31/2554\">",
"           Overview of nerve conduction studies",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Focal nerve syndromes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14570\">",
"           Polyradiculopathy: spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inflammatory myopathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/4/27722\">",
"           Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/23/15735\">",
"           Clinical manifestations and diagnosis of inclusion body myositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/22/11626\">",
"           Initial treatment of dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/7/24697\">",
"           Interstitial lung disease in dermatomyositis and polymyositis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38566\">",
"           Malignancy in dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4695\">",
"           Muscle disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/43/29368\">",
"           Pathogenesis and clinical manifestations of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/8/42121\">",
"           Pathogenesis of inflammatory myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/11/32950\">",
"           Pyomyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/30/28133\">",
"           Treatment and prognosis of inclusion body myositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/5/2138\">",
"           Treatment and prognosis of juvenile dermatomyositis and polymyositis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/48/13065\">",
"           Treatment of recurrent and resistant dermatomyositis and polymyositis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/41/9879\">",
"           Viral myositis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Inherited muscle disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/56/905\">",
"           Approach to the metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/36/21065\">",
"           Causes of metabolic myopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/16/1290\">",
"           Clinical features and diagnosis of Duchenne and Becker muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/58/21415\">",
"           Emery-Dreifuss muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6134\">",
"           Energy metabolism in muscle",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/34/26153\">",
"           Facioscapulohumeral muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/31/44530\">",
"           Lactate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/32/15881\">",
"           Limb-girdle muscular dystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/20/17736\">",
"           Lysosomal acid maltase deficiency (glycogen storage disease II, Pompe disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/19/43315\">",
"           Lysosome-associated membrane protein 2 deficiency (glycogen storage disease IIb, Danon disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/12/7370\">",
"           Mitochondrial myopathies: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/30/2536\">",
"           Mitochondrial myopathies: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/35/12853\">",
"           Mitochondrial structure, function, and genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/23/23928\">",
"           Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/26/19882\">",
"           Myotonic dystrophy: Etiology, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/40/18057\">",
"           Myotonic dystrophy: Prognosis and management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/14/41192\">",
"           Oculopharyngeal, distal, and congenital muscular dystrophies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/35/40500\">",
"           Other disorders of glycogen metabolism: GLUT2 deficiency and aldolase A deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/16/4356\">",
"           Overview of inherited disorders of glucose and glycogen metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/59/28596\">",
"           Phosphofructokinase deficiency (glycogen storage disease VII, Tarui disease)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44341\">",
"           Phosphoglycerate kinase deficiency and phosphoglycerate mutase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/2/26666\">",
"           Treatment of Duchenne and Becker muscular dystrophy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Motor system diseases",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/21/40280\">",
"           Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/34/16938\">",
"           Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/44/23240\">",
"           Disease modifying treatment of amyotrophic lateral sclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/57/23450\">",
"           Epidemiology and pathogenesis of amyotrophic lateral sclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/48/16138\">",
"           Familial amyotrophic lateral sclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/44/36553\">",
"           Polio and infectious diseases of the anterior horn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/45/5849\">",
"           Post-polio syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/26/33193\">",
"           Symptom-based management of amyotrophic lateral sclerosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuromuscular junction disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/17/11546\">",
"           Chronic immunomodulating therapies for myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/9/35992\">",
"           Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/51/17206\">",
"           Clinical manifestations of myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/12/32968\">",
"           Diagnosis of myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/18/15654\">",
"           Differential diagnosis of myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/45/36567\">",
"           Management of myasthenia gravis in pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/10/6311\">",
"           Myasthenic crisis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/53/7001\">",
"           Ocular myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/45/41688\">",
"           Overview of neuromuscular junction toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/35/31287\">",
"           Pathogenesis of myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/59/41910\">",
"           Thymectomy for myasthenia gravis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/43/2744\">",
"           Treatment of Lambert-Eaton myasthenic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/57/7066\">",
"           Treatment of myasthenia gravis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neuropathies",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/22/5481\">",
"           Clinical features and diagnosis of Guillain-Barr syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/32/8712\">",
"           Differential diagnosis of peripheral nerve and muscle disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/60/43976\">",
"           Neuromuscular weakness related to critical illness",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40038\">",
"           Pathogenesis of Guillain-Barr syndrome in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/14/14570\">",
"           Polyradiculopathy: spinal stenosis, infectious, carcinomatous, and inflammatory nerve root syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/16/265\">",
"           Treatment and prognosis of Guillain-Barr syndrome in adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-BE253B3A62-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f28_34_29231=[""].join("\n");
var outline_f28_34_29231=null;
           